Prof Henry Krum - Researcher Profile
Address
School of Public Health and Preventive MedicineMonash University
Biography
Henry Krum completed his MBBS at the University of Melbourne in 1981, became a Fellow of the Royal Australasian College of Physicians in 1989 and completed a PhD at the University of Melbourne in 1991.
Prof Krum is Chair of Medical Therapeutics, Professor of Medicine and Director of the Monash Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology & Preventive Medicine and Department of Medicine.
Prof Krum is a recognised leader in cardiovascular therapeutics, particularly in the area of novel cardiovascular drug therapies. This is attested to by his publication record, grant success and invitations to give plenary talks at major international meetings. He is currently Editor-in-Chief, Associate Editor and/or Editorial Board member of many international cardiovascular therapeutics journals and former President of the Asian Pacific Society of Heart Failure. Prof Krum has been Chairman and Executive Committee member of numerous international clinical trials as well as serving on Endpoint Committees and DSMBs for such trials. He was recently appointed Study Chairman of a 7000 patient global heart failure trial. He has in addition led many investigator-initiated trials of cardiovascular therapeutic agents.
The procedure Henry is developing involves putting in a catheter to disrupt nerves near the kidneys - the kidneys are in fact a major source of the hormones that influence blood pressure.
“This takes place in a half-hour procedure all up, then the actual device is withdrawn and the patient goes on their way. There’s no hardware left behind. The result in patients with very high hypertension is a very nice reduction in blood pressure,” says Henry.
This is a substantial improvement over previous attempts at renal denervation:
“In the 40s and 50s there was a similar surgery that succeeded in lowering blood pressure. However, it left patients with major problems – for example, they couldn’t stand up without fainting. This new approach has all the benefits in terms of blood pressure reduction, but none of the fifty patients involved in the initial trial have displayed any long-term adverse effects. In fact, subjects displayed progressive improvements as early as a month after treatments.”
Henry is currently the global principal investigator in the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE, or ‘ATMOSPHERE’. Swiss pharmaceutical company Novartis is the sponsor, and they have engaged a team of close collaborators throughout Europe and the United States to work around the world in 800 sites, with 7000 patients.
“This is a study of new agent called a direct renin inhibitor. It’s a new way of unblocking a system that’s been blocked with older drugs for some time. We won’t know whether the theoretical advantages translate into real actual advantages until after we’ve done the trial. In any case, it’s quite an honour to be the principle investigator for a global trial.”
Henry is particularly eager to help assist Monash students involved in his field.
“I think I’m the only clinical pharmacologist in the whole Monash system, and we need more. I think it would be good for Monash to have more clinical pharmacologist down here providing hospital-related services.”
Related Links:
Keywords
Cardiovascular Diseases, Clinical and pre-clinical trials, Clinical pharmacology, Heart failure
Publications
Books
Abraham, W., Krum, H., 2007, Heart failure: a practical approach to treatment, McGraw Hill, USA.
Willenheimer, R., Krum, H., 2007, New Insights into Early Drug Treatment of Chronic Heart Failure, Sherborne Gibbs Limited, United Kingdom.
Book Chapters
Haas, S.J., Thien, F., Tonkin, A.M., Kong, D.C.M., Nelson, M.R., Demos, L.L., Zimmet, H.S., Krum, H., Liew, D.Y.H., McNeil, J.J., 2009, Clozapine-associated myocarditis and cardiomyopathy - It's the heart that is important, not the classification, in Cardiomyopathies, Effects and Treatments, eds Peter H. Bruno & Matthew T. Giordano, Nova Science Publishers, New York, pp. 251-283.
Krum, H., Schlaich, M., Sobotka, P., 2008, Hypertension at the limits: Novel therapeutic approaches to the management of systemic hypertension, in Cardiology at the limits X, eds Lionel H Opie, Derek M Yellon, UCT Press, South Africa, pp. 63-87.
Krum, H., 2007, Ancillary pharmacologic therapies for heart failure, in Heart Failure: A practical approach to treatment, eds William T Abraham and Henry Krum, McGraw-Hill, USA, pp. 171-179.
Krum, H., 2007, Comorbidities and heart failure, in Heart Failure: A practical approach to treatment, eds William T Abraham and Henry Krum, McGraw-Hill, USA, pp. 225-239.
Krum, H., Martin, J., 2007, Novel drug treatments for hypertension, in Comprehensive Hypertension, eds Gregory Y H Lip and John E Hall, Mosby Inc., USA, pp. 1049-1060.
Krum, H., 2006, Beta-blocker therapy for heart failure, in Congestive Heart Failure, eds Jeffrey D Hosenpud and Barry H Greenberg, Lippincott Williams & Wilkins, USA, pp. 510-520.
Krum, H., Martin, J., Haas, S.J., Gilbert, R., 2003, Metabolic comorbid conditions in chronic heart failure: diabetes and hypercholesterolaemia, in Heart Failure Updates, eds John JV McMurray and Marc A Pfeffer, Martin Dunitz, London UK, pp. 35-57.
Todd, F., McLean, S., Krum, H., Martin, J., Copeland, J., 2002, Cannabis, in Management of Alcohol and Drug Problems, eds G Hulse, J White, G Cape, Oxford University Press, UK, pp. 141-157.
White, J., Martin, J., Krum, H., McLean, S., Young, R., Saunders, J., 2002, Hallucinogens, in Management of Alcohol and Drug Problems, eds Gary Hulse, Jason White, Gavin Cape, Oxford University Press, South Melbourne Vic Australia, pp. 229-238.
Liew, D.Y., Krum, H., 2002, Hypertension with left ventricular dysfunction, in Cardiovascular clinical cases Specific Treatment Strategies, eds Professor Franz H Messerli, PAN Communications, UK, pp. 183-192.
Zheng, H., Krum, H., Katz, S., 2002, The role of reactive oxidative species in the pathogenesis of endothelial function in patients with chronic heart failure, in Oxidative stress and cardiac failure, eds Marrick Kukin, Valentin Fuster, Wiley-Blackwell, United States, pp. 241-263.
Krum, H., 2000, Beta-blockers in heart failure. Current status, in Optimising heart failure management, Adis International Ltd, Sydney NSW Australia, pp. 41-49.
Gilbert, R., Cooper, M.E., Krum, H., 2000, Safety issues in drug therapy of the diabetic patient, in Drug treatment of type 2 diabetes, Adis International Ltd, Auckland NZ, pp. 45-60.
McNeil, J.J., Krum, H., 1997, Cardiovascular Disorders, in Avery's Drug Treatment, Adis International Limited, Auckland New Zealand, pp. 809-896.
Journal Articles
See, F., Watanabe, M., Kompa, A.R., Wang, B.H., Boyle, A., Kelly, D.J., Gilbert, R.E., Krum, H., 2013, Early and delayed tranilast treatment reduces pathological fibrosis following myocardial infarction, Heart Lung and Circulation [P], vol 22, Elsevier Australia, Australia, pp. 122-132.
Coller, J.M., Campbell, D.J., Krum, H., Prior, D.L., 2012, Early Identification of Asymptomatic Subjects at Increased Risk of Heart Failure and Cardiovascular Events-Progress and Future Directions., Heart Lung and Circulation [P], vol e-pub, Elsevier Australia, Australia, pp. 1-8.
Komajda, M., Bohm, M., Borer, J.S., Ford, I., Krum, H., Tase, A., Tavazzi, L., Swedberg, K., 2013, Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure, European Journal of Heart Failure [P], vol 15, issue 1, Oxford University Press, United Kingdom, pp. 79-84.
Campbell, D.J., McGrady, M., Prior, D.L., Coller, J.M., Boffa, U., Shiel, L.M., Liew, D.Y.H., Wolfe, R.S.J., Stewart, S., Reid, C.M., Krum, H., 2013, Most individuals with treated blood pressures above target receive only one or two antihypertensive drug classes: cross-sectional study of Australian at increased cardiovascular risk, Internal Medicine Journal [P], vol 43, issue 2, Wiley-Blackwell Publishing Asia, Australia, pp. 137-143.
Dobre, D., Rossignol, P., Murin, J., Parkhomenko, A., Lamiral, Z., Krum, H., Van Veldhuisen, D.J., Pitt, B., Zannad, F., 2013, Statin therapy and clinical outcomes in myocardial infarction patients complicated by acute heart failure: insights from the EPHESUS trial, European Journal of Heart Failure [P], vol 15, issue 2, Oxford University Press, United Kingdom, pp. 221-227.
Hopper, I., Skiba, M.A., Krum, H., 2012, Updated meta-analysis on antithrombotic therapy in patients with heart failure and sinus rhythm, European Journal of Heart Failure [P], vol e-pub, Oxford University Press, United Kingdom, pp. 1-10.
Chang, S., Davidson, P., Newton, P., Krum, H., Salamonson, Y., MacDonald, P., 2013, What is the methodological and reporting quality of health related quality of life in chronic heart failure clinical trials?, International Journal of Cardiology [P], vol e-pub, issue 2, Elsevier Ireland Ltd, Ireland, pp. 1-8.
Zhang, Y., Elsik, M., Edgley, A.J., Cox, A., Kompa, A.R., Wang, B.H., Tan, C.Y., Khong, F.L., Stapleton, D.I., Zammit, S.C., Williams, S.J., Gilbert, R.E., Krum, H., Kelly, D.J., 2012, A new anti-fibrotic drug attenuates cardiac remodeling and systolic dysfunction following experimental myocardial infarction, International Journal of Cardiology [P], vol e-pub, issue 1, Elsevier Ireland Ltd, Ireland, p. 12.
Krum, H., Lemke, B., Birnie, D., Lee, K.L., Aonuma, K., Starling, R.C., Gasparini, M., Gorcsan, J., Rogers, T., Sambelashvili, A., Kalmes, A., Martin, D., 2012, A novel algorithm for individualized cardiac resynchronization therapy: Rationale and design of the adaptive cardiac resynchronization therapy trial, American Heart Journal [P], vol 163, issue 5, Moby-Elsevier, United States, pp. 747-752.
Gilbert, R.E., Zhang, Y., Williams, S.J., Zammit, S.C., Stapleton, D.I., Cox, A., Krum, H., Langham, R.G., Kelly, D.J., 2012, A purpose-synthesised anti-fibrotic agent attenuates experimental kidney diseases in the rat, PLoS ONE [P], vol 7, issue 10, Public Library of Science, United States, pp. 1-15.
McMurray, J.J., Abraham, W., Dickstein, K., Kober, L., Massie, B.M., Krum, H., 2012, Aliskiren, altitude, and the implications for atmosphere, European Journal of Heart Failure [P], vol 14, Oxford University Press, Netherlands, pp. 341-343.
Liu, S., Wang, B.H., Kompa, A.R., Lekawanvijit, S., Krum, H., 2012, Antagonists of organic anion transporters 1 and 3 ameliorate adverse cardiac remodelling induced by uremic toxin indoxyl sulfate, International Journal of Cardiology [P], vol epub, Elsevier Ireland Ltd, Ireland, pp. 457-458.
Chang, S., Newton, P.J., Inglis, S.C., Luckett, T.L., Krum, H., Macdonald, P.S., Davidson, P.M., 2012, Are all outcomes in chronic heart failure rated equally? An argument for a patient-centred approach to outcome assessment, Heart Failure Reviews [E], vol epub, Springer New York LLC, New York, United States, pp. 1-10.
Iyngkaran, P., Schneider, H., Devarajan, P., Anavekar, N., Krum, H., Ronco, C., 2012, Cardio-renal syndrome: New perspective in diagnostics, Seminars in Nephrology [P], vol 32, issue 1, WB Saunders Co- Elsevier Inc, United States, pp. 3-17.
Liu, S., Lekawanvijit, S., Kompa, A., Wang, B., Kelly, D., Krum, H., 2012, Cardiorenal syndrome: pathophysiology, preclinical models, management and potential role of uraemic toxins, Clinical and Experimental Pharmacology and Physiology [E], vol 39, issue 8, Wiley-Blackwell Publishing Asia, Australia, pp. 692-700.
Lekawanvijit, S., Kompa, A.R., Wang, B.H., Kelly, D.J., 2012, Cardiorenal syndrome: the emerging role of protein-bound uremic toxins, Circulation Research [P], vol 111, issue 11, Lippincott Williams & Wilkins, United States, pp. 1470-1483.
Lekawanvijit, S., Kompa, A.R., Manabe, M., Wang, B.H., Langham, R.G., Nishijima, F., Kelly, D.J., Krum, H., 2012, Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate, PLoS ONE [P], vol 7, issue 7 (Art. No: e41281), Public Library of Science, United States, pp. 1-9.
Takeda, A., Taylor, S., Taylor, R.S., Khan, F., Krum, H., Underwood, M., 2012, Clinical service organisation for heart failure, Cochrane Database of Systematic Reviews [P], vol 9, issue Art. ID: CD002752, John Wiley & Sons Ltd, United Kingdom, pp. 1-158.
Rosenson, R., Horowitz, J., Kaski, J., Krum, H., Remme, W., 2012, Clinical trials update ESC congress 2011, Cardiovascular Drugs And Therapy [P], vol 26, Springer, United States, pp. 77-84.
von Lueder, T.G., Krum, H., 2012, Current modalities for invasive and non-invasive monitoring of volume status in heart failure, Heart [P], vol 98, BMJ Publishing group, England, pp. 967-973.
Stewart, S., Carrington, M., Swemmer, C.H., Anderson, C.S., Kurstjens, N.P., Amerena, J., Brown, A., Burrell, L.M., de Looze, F.J., Harris, M.F., Hung, J., Krum, H., Nelson, M., Schlaich, M.P., Stocks, N., Jennings, G.L.R., 2012, Effect of intensive structured care on individual blood pressure targets in primary care: Multicentre randomised controlled trial, British Medical Journal [P], vol 345, issue 7884, BMJ Publishing Group, London, United Kingdom, pp. 457-472.
Schlaich, M., Hering, D., Sobotka, P., Krum, H., Lambert, G., Lambert, E., Esler, M.D., 2012, Effects of renal denervation on sympathetic activation, blood pressure, and glucose metabolism in patients with resistant hypertension, Frontiers in Physiology [E], vol 3, issue Art. ID: 10, Frontiers Research Foundation, Switzerland, pp. 1-7.
Swedberg, K., Zannad, F., McMurray, J.J., Krum, H., Van Veldhuisen, D.J., Shi, H., Vincent, J., Pitt, B., 2012, Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study, Journal of the American College of Cardiology [P], vol 59, issue 18, Elsevier Science Ltd, United States, pp. 1598-1603.
Preiss, D., Van Veldhuisen, D.J., Sattar, N., Krum, H., Swedberg, K., Shi, H., Vincent, J., Pocock, S.J., Pitt, B., Zannad, F., McMurray, J.J., 2012, Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF), European Journal of Heart Failure [P], vol 14, issue 8, Oxford University Press, UK, pp. 909-915.
Watanabe, M., Krum, H., 2012, Eplerenone for the treatment of cardiovascular disorders, Expert Review of Cardiovascular Therapy [P], vol 10, issue 7, Expert Reviews Ltd, United Kingdom, pp. 831-838.
Rogers, J.K., McMurray, J.J.V., Pocock, S.J., Zannad, F., Krum, H., Van Veldhuisen, D.J., Swedberg, K., Shi, H., Vincent, J., Pitt, B., 2012, Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations, Circulation [P], vol 126, issue 19, Lippincott Williams & Wilkins, United States, pp. 2317-2323.
Zhang, Y., Edgley, A.J., Cox, A.J., Powell, A.K., Wang, B.H., Kompa, A.R., Stapleton, D.I., Zammit, S.C., Williams, S.J., Krum, H., Gilbert, R.E., Kelly, D.J., 2012, FT011, a new anti-fibrotic drug, attenuates fibrosis and chronic heart failure in experimental diabetic cardiomypathy, European Journal of Heart Failure [P], vol 14, Oxford University Press, Netherlands, pp. 549-562.
Tan, S.M., Zhang, Y., Wang, B.H., Tan, C.Y., Zammit, S.C., Williams, S.J., Kelly, D.J., Krum, H., 2012, FT23, an orally active antifibrotic compound, attenuates structural and functional abnormalities in an experimental model of diabetic cardiomyopathy, Clinical And Experimental Pharmacology And Physiology [P], vol 39, issue 8, Wiley-Blackwell Publishing Asia, Australia, pp. 650-656.
Lambert, G.W., Hering, D., Esler, M.D., Marusic, P., Lambert, E., Tanamas, S.K., Shaw, J.E., Krum, H., Dixon, J., Barton, D.A., Schlaich, M., 2012, Health-related quality of life after renal denervation in patients with treatment-resistant hypertension, Hypertension [P], vol 60, issue 6, Lippincott Williams & Wilkins, United States, pp. 1479-1484.
McGrady, M., Krum, H., Carrington, M., Stewart, S., Zeitz, C.J., Lee, G.A., Marwick, T.H., Haluska, B., Brown, A., 2012, Heart failure, ventricular dysfunction and risk factor prevalence in Australian Aboriginal peoples: the Heart of the Heart Study, Heart [P], vol 98, issue 21, B M J Group, United Kingdom, pp. 1562-1567.
Hopper, I., Kemp, W., Porapakkham, P., Sata, Y., Condon, E., Skiba, M., Forber, L., Porapakkham, P., Williams, T., Menahem, S., Roberts, S., Krum, H., 2012, Impact of heart failure and changes to volume status on liver stiffness: non-invasive assessment using transient elastography, European Journal of Heart Failure [P], vol 14, issue 6, Oxford University Press, United Kingdom, pp. 621-627.
Stewart, S., Carrington, M., Marwick, T.H., Davidson, P., Macdonald, P.S., Horowitz, J.D., Krum, H., Newton, P.J., Reid, C.M., Chan, Y.K., Scuffham, P., 2012, Impact of home versus clinic-based management of chronic heart failure: the WHICH? (Which Heart Failure Intervention Is Most Cost-Effective & Consumer Friendly in Reducing Hospital Care) multicenter, randomized trial., Journal of the American College of Cardiology [P], vol 60, issue 14, Elsevier Inc., United States, pp. 1239-1248.
Suarez, J., Piccini, J.P., Liang, L., Atherton, J.J., Hayward, C.S., Krum, H., Fonarow, G.C., Lopes, R.D., Hernandez, A.F., 2012, International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation, American Heart Journal [P], vol 163, issue 5, Moby-Elsevier, United States, pp. 804-811.
Martin, D.O., Lemke, B., Birnie, D., Krum, H., Lee, K., Aonuma, K., Gasparini, M., Starling, R.C., Milasinovic, G., Rogers, T., Sambelashvili, A., Gorcsan, J., Houmsse, M., 2012, Investigation of a novel algorithm for synchronized left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy: results of the adaptive CRT trial, Heart Rhythm [P], vol 9, issue 11, Elsevier Inc., United States, pp. 1807-1814.
Krum, H., Lang, C., 2012, Mind your language: Conveying the results of clinical trials of cardiovascular therapies, Cardiovascular Therapeutics [P], vol epub, Wiley-Blackwell Publishing Ltd., United Kingdom, p. A.
Lekawanvijit, S., Kompa, A., Zhang, Y., Wang, B., Kelly, D., Krum, H., 2012, Myocardial infarction impairs renal function, induces renal interstitial fibrosis and increases KIM-1 expression: Implications for the cardiorenal syndrome, American Journal of Physiology - Heart and Circulatory Physiology [E], vol epub, American Physiological Society, United States, pp. 1-11.
Aronson, D., Krum, H., 2012, Novel therapies in acute and chronic heart failure, Pharmacology and Therapeutics [P], vol 135, Elsevier Science Ltd, United States, pp. 1-17.
Driscoll, A., Currey, J., Tonkin, A.M., Krum, H., 2012, Nurse-led titration of angiotensin converting enzyme inhibitors, beta-adrenergic blocking agents and angiotensin receptor blockers for patients with left ventricular systolic dysfunction (Protocol), Cochrane Database of Systematic Reviews [P], vol 6, issue Art. ID: CD009889, John Wiley & Sons Ltd, United Kingdom, pp. 1-9.
Atherton, J., Hayward, C., Wan, W.A., Kwok, B., Jorge, J., Hernandez, A., Liang, L., Kociol, R., Krum, H., 2012, Patient characteristics from a regional multicenter database of acute decompensated heart failure in Asia Pacific (ADHERE International-Asia Pacific), Journal Of Cardiac Failure [P], vol 18, issue 1, Churchill Livingstone, United States, pp. 82-88.
Wang, B.H., Reisman, S., Bailey, M., Kompa, A.R., Ayhan, M., Krum, H., Rice, G.E., 2012, Peptidomic profiles of post myocardial infarction rats affinity depleted plasma using matrix-assisted laser desorption/ionization time of flight (MALDI-ToF) mass spectrometry, Clinical and translational medicine [E], vol 1, issue Art. No: 11, SpringerOpen, United States, pp. 1-8.
von Lueder, T.G., Krum, H., 2012, RAAS inhibitors and cardiovascular protection in large scale trials, Cardiovascular Drugs and Therapy [E], vol epub, Springer New York LLC, New York, United States, p. 9.
Kotecha, D., New, G., Collins, P., Eccleston, D., Krum, H., Pepper, J., Flather, M., 2012, Radial artery pulse wave analysis for non-invasive assessment of coronary artery disease, International Journal of Cardiology [P], vol epub, Elsevier Ireland Ltd, Ireland, pp. 1-8.
Pitt, B., Filippatos, G., Gheorghiade, M., Kober, L., Krum, H., Ponikowski, P., Nowack, C., Kolkhof, P., Kim, S., Zannad, F., 2012, Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease, European Journal of Heart Failure [P], vol 14, issue 6, Oxford University Press, Netherlands, pp. 668-675.
Schlaich, M., Hering, D., Sobotka, P., Krum, H., Esler, M.D., 2012, Renal denervation in human hypertension: mechanisms, current findings, and future prospects, Current Hypertension Reports [P], vol 14, issue 3, Springer Healthcare, United States, pp. 247-253.
Hering, D., Mahfoud, F., Walton, A., Krum, H., Lambert, G.W., Lambert, E., Sobotka, P., Bohm, M., Cremers, B., Esler, M.D., Schlaich, M., 2012, Renal denervation in moderate to severe CKD, Journal Of The American Society Of Nephrology [P], vol 23, issue 7, American Society of Nephrology, United States, pp. 1250-1257.
Mahfoud, F., Cremers, B., Janker, J., Link, B., Vonend, O., Ukena, C., Linz, D., Schmieder, R.E., Rump, L.C., Kindermann, I., Sobotka, P., Krum, H., Scheller, B., Schlaich, M., Laufs, U., Bohm, M., 2012, Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension, Hypertension [P], vol 60, issue 2, Lippincott Williams & Wilkins, United States, pp. 419-424.
Esler, M.D., Krum, H., Schlaich, M.P., Schmieder, R.E., Bohm, M., Sobotka, P., 2012, Renal sympathetic denervation for treatment of drug-resistant hypertension one-year results from the symplicity HTN-2 randomized, controlled trial, Circulation [P], vol 126, issue 25, Lippincott Williams & Wilkins, Baltimore, United States, pp. 2976-2982.
Kompa, A., Wang, B., Xu, G., Zhang, Y., Ho, P., Eisennagel, S., Thalji, R., Marina, J., Kelly, D., Behm, D., Krum, H., 2012, Soluble epoxide hydrolase inhibition exerts beneficial anti-remodeling actions post-myocardial infarction, International Journal of Cardiology [P], vol E, Elsevier Ireland Ltd, Ireland, pp. 1-10.
Hering, D., Lambert, E., Marusic, P., Walton, A., Krum, H., Lambert, G.W., Esler, M.D., Schlaich, M., 2012, Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension, Hypertension [P], vol 61, issue 2, Lippincott Williams & Wilkins, Philadelphia, United States, pp. 457-464.
Dworak, M., Stebbing, M., Kompa, A.R., Rana, I., Krum, H., Badoer, E., 2012, Sustained activation of microglia in the hypothalamic PVN following myocardial infarction, Autonomic Neuroscience: Basic and Clinical [P], vol 169, issue 2, Elsevier BV, Netherlands, pp. 70-76.
Edgley, A.J., Krum, H., Kelly, D.J., 2012, Targeting fibrosis for the treatment of heart failure: A role for transforming growth factor-, Cardiovascular Therapeutics [P], vol 30, Wiley-Blackwell, England, pp. 30-40.
Krum, H., Forbes, A.B., Yallop, J.J., Driscoll, A., Croucher, J.L., Chan, B.G.Y., Clark, R., Davidson, P., Huynh, L., Kasper, E.K., Hunt, D., Egan, H., Stewart, S., Piterman, L., Tonkin, A.M., 2012, Telephone support to rural and remote patients with heart failure: the Chronic Heart failure Assessment by Telephone (CHAT) study, Cardiovascular Therapeutics [P], vol epub, Wiley-Blackwell Publishing Ltd., United Kingdom, pp. 1-32.
Newton, P.J., Davidson, P., Krum, H., Ollerton, R., Macdonald, P.S., 2012, The acute haemodynamic effect of nebulised frusemide in stable, advanced heart failure, Heart Lung and Circulation [P], vol 21, Elsevier Science Ltd, Australia, pp. 260-266.
Sobotka, P., Krum, H., Bohm, M., Francis, D.P., Schlaich, M., 2012, The role of renal denervation in the treatment of heart failure, Current Cardiology Reports [E], vol 14, issue 3, Springer, England, pp. 285-292.
Coller, J.M., Campbell, D.J., Krum, H., Prior, D.L., 2012, Transthoracic echocardiography findings: Implications for clinical management, Australian Family Physician [P], vol 41, issue 12, Royal Australian College of General Practitioners, South Melbourne, Australia, pp. 954-958.
Krum, H., Jelinek, M., Stewart, S., Sindone, A., Atherton, J., 2011, 2011 update to National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006, Medical Journal Of Australia [P], vol 194, issue 8, Australasian Medical Publishing Company Pty. Ltd, Australia, pp. 405-409.
Khong, F., Zhang, Y., Edgley, A., Qi, W., Connelly, K., Woodman, O., Krum, H., Kelly, D., 2011, 3',4'-Dihydroxyflavonol antioxidant attenuates diastolic dysfunction and cardiac remodeling in streptozotocin-induced diabetic m(Ren2)27 rats, PLoS ONE [P], vol 6, issue 7 (Art. No: e22777), Public Library of Science, United States, pp. 1-14.
Krum, H., Swergold, G., Gammaitoni, A., Peloso, P., Smugar, S., Curtis, S., Brater, D.C., Wang, H., Kaur, A., Laine, L., Weir, M., Cannon, C., 2011, Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs, Cardiovascular Therapeutics [P], vol E, Wiley-Blackwell Publishing Ltd, UK, pp. 1-9.
Ukena, C., Mahfoud, F., Kindermann, I., Barth, C., Lenski, M., Kindermann, M., Brandt, M., Hoppe, U., Krum, H., Esler, M., Sobotka, P., Bohm, M., 2011, Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension, Journal of the American College of Cardiology [P], vol 58, issue 11, Elsevier Inc., United States, pp. 1176-1182.
Krum, H., Barman, N., Schlaich, M., Sobotka, P., Esler, M., Mahfoud, F., Bohm, M., Dunlap, M., 2011, Catheter-based renal sympathetic denervation for resistant hypertension, Hypertension [P], vol 57, Lippincott Williams & Wilkins, United States, pp. 911-917.
Connelly, K., Advani, A., Advani, S., Zhang, Y., Thai, K., Thomas, S., Krum, H., Kelly, D., Gilbert, R., 2011, Combination angiotensin converting enzyme and direct renin inhibition in heart failure following experimental myocardial infarction, Cardiovascular Therapeutics [P], vol E, Wiley-Blackwell Publishing Ltd, UK, pp. 1-8.
Krum, H., Sobotka, P., Mahfoud, F., Bohm, M., Esler, M., Schlaich, M., 2011, Device-based antihypertensive therapy: Therapeutic modulation of the autonomic nervous system, Circulation [P], vol 123, issue 2, Lippincott Williams & Wilkins, United States, pp. 209-215.
Krum, H., Massie, B., Abraham, W., Dickstein, K., Kober, L., McMurray, J., Desai, A., Gimpelewicz, C., Kandra, A., Reimund, B., Rattunde, H., Armbrecht, J., 2011, Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (, European Journal of Heart Failure [P], vol 13, Oxford University Press, United Kingdom, pp. 107-114.
O'Connor, C., Starling, R., Hernandez, A., Armstrong, P., Dickstein, K., Hasselblad, V., Heizer, G., Komajda, M., Massie, B., McMurray, J., Nieminen, M., Reist, C., Rouleau, J., Swedberg, K., Adams, K., Anker, S., Atar, D., Battler, A., Botero, R., Bohidar, N., Butler, J., Clausell, N., Corbalan, R., Costanzo, M., Dahlstrom, U., Deckelbaum, L., Diaz, R., Dunlap, M., Ezekowitz, J., Feldman, D., Felker, G., Fonarow, G., Gennevois, D., Gottlieb, S., Hill, J., Hollander, J., Howlett, J., Hudson, M., Kociol, R., Krum, H., Laucevicius, A., Levy, W., Mendez, G., Metra, M., Mittal, S., Oh, B., Pereira, N., Ponikowski, P., Wilson Tang, W., Tanomsup, S., Teerlink, J., Triposkiadis, F., Troughton, R., Voors, A., Whellan, D., Zannad, F., Califf, R., 2011, Effect of nesiritide in patients with acute decompensated heart failure, New England Journal Of Medicine [P], vol 365, issue 1, Massachusetts Medical Society, United States, pp. 32-43.
Mahfoud, F., Schlaich, M., Kindermann, I., Ukena, C., Cremers, B., Brandt, M., Hoppe, U., Vonend, O., Rump, L., Sobotka, P., Krum, H., Esler, M., Bohm, M., 2011, Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: A pilot study, Circulation [P], vol 123, issue 18, Lippincott Williams & Wilkins, United States, pp. 1940-1946.
Krum, H., Van Veldhuisen, D.J., Funck-Brentano, C., Vanoli, E., Silke, B., Erdmann, E., Follath, F., Ponikowski, P., Goulder, M., Meyer, W., Lechat, P., Willenheimer, R., 2011, Effect on mode of death of heart failure treatment started with bisoprolol followed by enalapril, compared to the opposite order: Results of the randomized CIBIS III trial, Cardiovascular Therapeutics [P], vol 29, issue 2, Wiley-Blackwell Publishing Ltd, United Kingdom, pp. 89-98.
Calhoun, D., White, W., Krum, H., Guo, W., Bermann, G., Trapani, A., Lefkowitz, M., Menard, J., 2011, Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension, Circulation [E], vol 124, issue 18, Lippincott Williams & Wilkins, United States, pp. 1945-1955.
Badve, S., Roberts, M., Hawley, C., Cass, A., Garg, A., Krum, H., Tonkin, A., Perkovic, V., 2011, Effects of beta-adrenergic antagonists in patients with chronic kidney disease: A systematic review and meta-analysis, Journal of the American College of Cardiology [P], vol 58, issue 11, Elsevier Inc., United States, pp. 1152-1161.
Tran, L., Kompa, A., Wang, B., Krum, H., 2011, Evaluation of the effects of Urotensin II and soluble epoxide hydrolase inhibitor on skin microvessel tone in healthy controls and heart failure patients, Cardiovascular Therapeutics [P], vol E, Wiley-Blackwell Publishing Ltd, UK, pp. 1-6.
Kotecha, D., New, G., Flather, M., Eccleston, D., Pepper, J., Krum, H., 2011, Five-minute heart rate variability can predict obstructive angiographic coronary disease, Heart [P], vol E, B M J Group, United Kingdom, pp. 1-7.
Lu, K., Yan, B., Ajani, A., Wilson, W., Duffy, S., Gurvitch, R., Clark, D., Brennan, A., Reid, C., Andrianopoulos, N., Krum, H., 2011, Impact of concomitant heart failure on outcomes in patients undergoing percutaneous coronary interventions: Analysis of the Melbourne Interventional Group registry, European Journal of Heart Failure [P], vol 13, issue 4, Oxford University Press, United Kingdom, pp. 416-422.
Krum, H., Teerlink, J., 2011, Medical therapy for chronic heart failure, Lancet [P], vol 378, issue 9792, The Lancet Publishing Group, UK, pp. 713-721.
Krum, H., Schlaich, M., Sobotka, P., Scheffers, I., Kroon, A., De Leeuw, P., 2011, Novel procedure and device-based strategies in the management of systemic hypertension, European Heart Journal [P], vol 32, issue 5, Oxford University Press, United Kingdom, pp. 537-544.
Driscoll, A., Krum, H., Wolfe, R., Tonkin, A., 2011, Nurse-led titration of beta-adrenoreceptor blocking agents in chronic heart failure patients in the community, Journal Of Cardiac Failure [P], vol 17, issue 3, Churchill Livingstone, United States, pp. 224-230.
Hopper, I., Billah, M., Skiba, M., Krum, H., 2011, Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: Meta-analysis of randomised controlled clinical trials, European Journal Of Cardiovascular Prevention & Rehabilitation [P], vol 18, issue 6, Sage Publications Ltd, UK, pp. 813-823.
Hering, D., Esler, M., Krum, H., Mahfoud, F., Bohm, M., Sobotka, P., Schlaich, M., 2011, Recent advances in the treatment of hypertension, Expert Review of Cardiovascular Therapy [P], vol 9, issue 6, Expert Reviews Ltd., UK, pp. 729-744.
Krum, H., Elsik, M., Schneider, H., Ptaszynska, A., Black, M., Carson, P., Komajda, M., Massie, B., McKelvie, R., McMurray, J., Zile, M., Anand, I., 2011, Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen substudy, Circulation: Heart Failure [P], vol 4, issue 5, Lippincott Williams & Wilkins, United States, pp. 561-568.
Schlaich, M., Krum, H., Sobotka, P., Esler, M., 2011, Renal denervation and hypertension, American Journal of Hypertension [P], vol 24, issue 6, Nature Group Publishing, United States, pp. 635-642.
Schlaich, M., Straznicky, N., Grima, M., Ika-Sari, C., Dawood, T., Mahfoud, F., Lambert, E., Chopra, R., Socratous, F., Hennebry, S., Eikelis, N., Bohm, M., Krum, H., Lambert, G., Esler, M., Sobotka, P., 2011, Renal denervation: A potential new treatment modality for polycystic ovary syndrome?, Journal of Hypertension [P], vol 28, issue 5, Lippincott Williams & Wilkins, Ltd, United Kingdom, pp. 991-996.
Hering, D., Walton, A., Krum, H., Lambert, G., Esler, M., Schlaich, M., 2011, Renal nerve ablation reduces blood pressure in a patient with renovascular hypertension resistant to drug and revascularisation therapies, International Journal of Cardiology [P], vol epub, Elsevier Ireland Ltd, Ireland, pp. 1-2.
Zimmet, H., Porapakkham, P., Porapakkham, P., Sata, Y., Haas, S., Itescu, S., Forbes, A., Krum, H., 2011, Short- and long-term outcomes of intracoronary and endogenously mobilized bone marrow stem cells in the treatment of ST-segment elevation myocardial infarction: A meta-analysis of randomized control trials, European Journal of Heart Failure [P], vol E, Oxford University Press, United Kingdom, pp. 1-15.
Aronson, D., Verbalis, J., Mueller, M., Krum, H., 2011, Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: The DILIPO study, European Journal of Heart Failure [P], vol 13, issue 3, Oxford University Press, United Kingdom, pp. 327-336.
Sobotka, P., Mahfoud, F., Schlaich, M., Hoppe, U., Bohm, M., Krum, H., 2011, Sympatho-renal axis in chronic disease, Clinical Research In Cardiology [P], vol 100, issue 12, Springer Medizin, Germany, pp. 1049-1057.
Krum, H., 2011, Telemonitoring of fluid status in heart failure: CHAMPION, Lancet [P], vol 377, The Lancet Publishing Group, United Kingdom, pp. 616-618.
Stewart, S., Carrington, M., Marwick, T., Davidson, P., Macdonald, P., Horowitz, J., Krum, H., Newton, P., Reid, C., Scuffham, P., 2011, The WHICH? trial: Rationale and design of a pragmatic randomized, multicentre comparison of home- vs. clinic-based management of chronic heart failure patients, European Journal of Heart Failure [P], vol 13, issue 8, Oxford University Press, United Kingdom, pp. 909-916.
Connelly, K., Advani, A., Kim, S., Advani, S., Zhang, M., White, K., Kim, Y., Parker, C., Thai, K., Krum, H., Kelly, D., Gilbert, R., 2011, The cardiac (pro)renin receptor is primarily expressed in myocyte transverse tubules and is increased in experimental diabetic cardiomyopathy, Journal of Hypertension [P], vol 29, issue 6, Lippincott Williams & Wilkins, Ltd, United Kingdom, pp. 1175-1184.
See, F., Seki, T., Psaltis, P., Sondermeijer, H., Gronthos, S., Zannettino, A., Goveart, K., Schuster, M., Kurlansky, P., Kelly, D., Krum, H., Itescu, S., 2011, Therapeutic effects of human STRO-3-selected mesenchymal precursor cells and their soluble factors in experimental myocardial ischemia, Journal Of Cellular And Molecular Medicine [P], vol 15, issue 10, Wiley-Blackwell, England, pp. 2117-2129.
Pawar, R., Kemp, W., Roberts, S., Krum, H., Yandle, T., Hardikar, W., 2011, Urotensin II levels are an important marker for the severity of portal hypertension in children, Journal Of Pediatric Gastroenterology And Nutrition [P], vol 53, issue 1, Lippincott Williams & Wilkins, United States, pp. 88-92.
Lokuge, A., Lam, L.L.Y., Cameron, P., Krum, H., De Villiers Smit, P., Bystrzycki, A., Naughton, M.T., Eccleston, D., Flannery, G., Federman, J., Schneider, H., 2010, B-type natriuretic peptide testing and the accuracy of heart failure diagnosis in the emergency department, Circulation: Heart Failure [P], vol 3, issue 1, Lippincott Williams & Wilkins, United States, pp. 104-110.
Porapakkham, P., Porapakkham, P., Zimmet, H., Billah, B., Krum, H., 2010, B-type natriuretic peptide-guided heart failure therapy: A meta-analysis, Archives of Internal Medicine [P], vol 170, issue 6, American Medical Association, United States, pp. 507-514.
Krum, H., McMurray, J., Horton, E., Gerlock, T., Holzhauer, B., Zuurman, L., Haffner, S., Bethel, M., Holman, R., Califf, R., 2010, Baseline characteristics of the nateglinide and valsartan impaired glucose tolerance outcomes research (NAVIGATOR) trial population: comparison with other diabetes prevention trials, Cardiovascular Therapeutics [P], vol 28, issue 2, Wiley-Blackwell Publishing Ltd, United Kingdom, pp. 124-132.
Wang, B., Bertucci, M., Ma, J., Adrahtas, A., Cheung, R., Krum, H., 2010, Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosterone, Clinical And Experimental Pharmacology And Physiology [P], vol 37, issue 9, Wiley-Blackwell Publishing Asia, Australia, pp. 912-918.
Kompa, A., Wang, B., Phrommintikul, A., Ho, P., Kelly, D., Behm, D., Douglas, S., Krum, H., 2010, Chronic urotensin II receptor antagonist treatment does not alter hypertrophy or fibrosis in a rat model of pressure-overload hypertrophy, Peptides [P], vol 31, issue 8, Elsevier Inc, United States, pp. 1523-1530.
Tran, L., Kompa, A., Kemp, W., Phrommintikul, A., Wang, B., Krum, H., 2010, Chronic urotensin-II infusion induces diastolic dysfunction and enhances collagen production in rats, American Journal Of Physiology-Heart And Circulatory Physiology [P], vol 298, issue 2, American Physiological Society, United States, pp. 608-613.
Kotecha, D., Flather, M., McGrady, M., Pepper, J., New, G., Krum, H., Eccleston, D., 2010, Contemporary predictors of coronary artery disease in patients referred for angiography, European Journal Of Cardiovascular Prevention & Rehabilitation [P], vol 17, Lippincott, Williams & Wilkins, United States, France, pp. 280-288.
Jabbour, A., Macdonald, P., Keogh, A., Kotlyar, E., Mellemkjaer, S., Coleman, C., Elsik, M., Krum, H., Hayward, C., 2010, Differences Between Beta-Blockers in Patients With Chronic Heart Failure and Chronic Obstructive Pulmonary Disease. A Randomized Crossover Trial, Journal of the American College of Cardiology [P], vol 55, issue 17, Elsevier Inc, United States, pp. 1780-1787.
Troughton, R., Ritzema-Carter, J., Eigler, N., Melton, I., Krum, H., Adamson, P., Kar, S., Shah, P., Whiting, J., Heywood, J., Rosero, S., Singh, J., Saxon, L., Matthews, R., Crozier, I., Abraham, W., 2010, Direct left atrial pressure monitoring in severe heart failure: Long-term sensor performance, Journal of Cardiovascular Translational Research [P], vol E, Springer New York LLC, United States, pp. 1-11.
Bakris, G., Lindholm, L., Black, H., Krum, H., Linas, S., Linseman, J., Arterburn, S., Sager, P., Weber, M., 2010, Divergent results using clinic and ambulatory blood pressures: Report of a darusentan-resistant hypertension trial, Hypertension [P], vol 56, issue 5, Lippincott Williams & Wilkins, United States, pp. 824-830.
Lekawanvijit, S., Adrahtas, A., Kelly, D., Kompa, A., Wang, B., Krum, H., 2010, Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes?, European Heart Journal [P], vol 31, Oxford University Press, UK, pp. 1771-1779.
Martin, J., Connelly, K., Boyle, A., Kompa, A.R., Zhang, Y., Kelly, D.J., Gilbert, R.E., Krum, H., 2010, Effect of atorvastatin on cardiac remodelling and mortality in rats following hyperglycemia and myocardial infarction, International Journal of Cardiology [P], vol 143, Elsevier Ireland Ltd, Ireland, pp. 353-360.
Holman, R., Haffner, S., McMurray, J., Bethel, M., Holzhauer, B., Hua, T., Belenkov, Y., Boolell, M., Buse, J., Buckley, B., Chacra, A., Chiang, F., Charbonnel, B., Chow, C., Davies, M., Deedwania, P., Diem, P., Einhorn, D., Fonseca, V., Fulcher, G., Gaciong, Z., Gaztambide, S., Giles, T., Horton, E., Ilkova, H., Jenssen, T., Kahn, S., Krum, H., Laakso, M., Leiter, L., Levitt, N., Mareev, V., Martinez, F., Masson, C., Mazzone, T., Meaney, E., Nesto, R., Pan, C., Prager, R., Raptis, S., Rutten, G., Sandstroem, H., Schaper, F., Scheen, A., Schmitz, O., Sinay, I., Soska, V., Stender, S., Tamas, G., Tognoni, G., Tuomilehto, J., Villamil, A., Vozar, J., Califf, R., 2010, Effect of nateglinide on the incidence of diabetes and cardiovascular events, New England Journal Of Medicine [P], vol 362, issue 16, Massachusetts Medical Society, United States, pp. 1463-1476.
Vogt, L., Chiurchiu, C., Chadha-Boreham, H., Danaietash, P., Dingemanse, J., Hadjadj, S., Krum, H., Navis, G., Neuhart, E., Parvanova, A., Ruggenenti, P., Woittiez, A., Zimlichman, R., Remuzzi, G., de Zeeuw, D., 2010, Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathy, Hypertension [P], vol 55, issue 5, Lippincott Williams & Wilkins, United States, pp. 1206-1209.
McMurray, J., Holman, R., Haffner, S., Bethel, M., Holzhauer, B., Hua, T., Belenkov, Y., Boolell, M., Buse, J., Buckley, B., Chacra, A., Chiang, F., Charbonnel, B., Chow, C., Davies, M., Deedwania, P., Diem, P., Einhorn, D., Fonseca, V., Fulcher, G., Gaciong, Z., Gaztambide, S., Giles, T., Horton, E., Ilkova, H., Jenssen, T., Kahn, S., Krum, H., Laakso, M., Leiter, L., Levitt, N., Mareev, V., Martinez, F., Masson, C., Mazzone, T., Meaney, E., Nesto, R., Pan, C., Prager, R., Raptis, S., Rutten, G., Sandstroem, H., Schaper, F., Scheen, A., Schmitz, O., Sinay, I., Soska, V., Stender, S., Tamas, G., Tognoni, G., Tuomilehto, J., Villamil, A., Vozar, J., Califf, R., 2010, Effect of valsartan on the incidence of diabetes and cardiovascular events, New England Journal Of Medicine [P], vol 362, Massachusetts Medical Society, United States, pp. 1477-1490.
Zannad, F., McMurray, J., Krum, H., Van Veldhuisen, D., Swedberg, K., Shi, H., Vincent, J., Pocock, S., Pitt, B., 2010, Eplerenone in patients with systolic heart failure and mild symptoms, New England Journal Of Medicine [P], vol 364, issue 1, Massachusetts Medical Society, United States, pp. 11-21.
Wein, S., Voskoboinik, A., Wein, L., Billah, M., Krum, H., 2010, Extending the boundaries of cardiac resynchronization therapy: Efficacy in atrial fibrillation, New York Heart Association Class II, and Narrow QRS heart failure patients, Journal Of Cardiac Failure [P], vol 16, issue 5, Churchill Livingstone, United States, Japan, pp. 432-438.
Porapakkham, P., Porapakkham, P., Krum, H., 2010, Is target dose of beta-blocker more important than achieved heart rate or heart rate change in patients with systolic chronic heart failure?, Cardiovascular Therapeutics [P], vol 28, issue 2, Wiley-Blackwell Publishing Ltd, United Kingdom, pp. 93-100.
Lam, L., Cameron, P., Schneider, H., Abramson, M., Mueller, C., Krum, H., 2010, Meta-analysis: Effect of B-type natriuretic peptide testing on clinical outcomes in patients with acute dyspnea in the emergency setting, Annals Of Internal Medicine [P], vol 153, issue 11, American College of Physicians, United States, pp. 728-735.
Rana, I., Stebbing, M., Kompa, A., Kelly, D., Krum, H., Badoer, E., 2010, Microglia activation in the hypothalamic PVN following myocardial infarction, Brain Research [P], vol 1326, Elsevier BV, Netherlands, pp. 96-104.
Schlaich, M., Krum, H., Esler, M., 2010, New therapeutic approaches to resistant hypertension, Current Hypertension Reports [P], vol 12, issue 4, Current Medicine Group LLC, United States, pp. 296-302.
Ritzema, J., Troughton, R., Melton, I., Crozier, I., Doughty, R., Krum, H., Walton, A., Adamson, P., Kar, S., Shah, P.K., Richards, M., Eigler, N.L., Whiting, J.S., Haas, G.J., Heywood, J.T., Frampton, C.M., Abraham, W.T., 2010, Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure, Circulation [P], vol 121, issue 9, Lippincott Williams & Wilkins, United States, pp. 1086-1095.
Thom, O., Taylor, D., Wolfe, R.E., Myles, P.S., Krum, H., Wolfe, R., 2010, Pilot study of the prevalence, outcomes and detection of occult hypoperfusion in trauma patients, Emergency Medicine Journal [P], vol 27, BMJ Group, United Kingdom, pp. 470-472.
Zannad, F., McMurray, J., Drexler, H., Krum, H., Van Veldhuisen, D., Swedberg, K., Shi, H., Vincent, J., Pitt, B., 2010, Rationale and design of the eplerenone in mild patients hospitalization and survival study in heart failure (EMPHASIS-HF), European Journal of Heart Failure [P], vol 12, Oxford University Press, United Kingdom, France, pp. 617-622.
Esler, M., Krum, H., Sobotka, P.A., Schlaich, M.P., Schmieder, R.E., Bohm, M., Mahfoud, F., Sievert, H., Wunderlich, N., Rump, L.C., Vonend, O., Uder, M., Lobo, M.D., Caulfield, M.J., Erglis, A., Azizi, M., Sapoval, M., Thambar, S., Persu, A., Renkin, J., Schunkert, H., Weil, J., Hoppe, U.C., Walton, A., Scheinert, D., Binder, T., Januszewicz, A., Witkowski, A., Ruilope, L., Whitbourn, R., Bruck, H., Downes, M., Luscher, T.F., Jardine, A.G.M., Webster, M.W., Zeller, T., Sadowski, J., Bartus, K., Straley, C.A., Barman, N., Lee, D.P., Witteles, R.M., Bhalla, V., Massaro, J.M., 2010, Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial, Lancet [P], vol 376, issue 9756, The Lancet Publishing Group, United Kingdom, pp. 1903-1909.
Schlaich, M., Krum, H., Sobotka, P., 2010, Renal sympathetic nerve ablation: The new frontier in the treatment of hypertension, Current Hypertension Reports [P], vol 12, issue 1, Current Medicine Group LLC, United States, pp. 39-46.
Krum, H., Maggioni, A., 2010, Renin inhibitors in chronic heart failure: The aliskiren observation of heart failure treatment study in context, Clinical Cardiology [P], vol 33, issue 9, John Wiley & Sons Inc, United States, pp. 536-541.
Sata, Y., Krum, H., 2010, The future of pharmacological therapy for heart failure, Circulation Journal [P], vol 74, issue 5, Japanese Circulation Society, Japan, pp. 809-817.
Ashton, E., Windebank, E., Skiba, M., Reid, C., Schneider, H., Rosenfeldt, F., Tonkin, A., Krum, H., 2010, Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study, International Journal of Cardiology [P], vol 146, issue 3, Elsevier Ireland Ltd, Ireland, pp. 404-407.
Leet, A., Richardson, M., Senior, J., Funston, R., Skiba, M.A., Bailey, M.J., Krum, H., 2009, A bioavailability study of cyclosporine: comparison of Neoral versus Cysporin in stable heart transplant recipients, Journal of Heart and Lung Transplantation [P], vol 28, issue 9, Elsevier Inc., United States, United Kingdom, France, pp. 894-898.
Weber, M., Black, H., Bakris, G.L., Krum, H., Linas, S., Weiss, R., Linseman, J.V., Wiens, B.L., Warren, M.S., Lindholm, L.H., 2009, A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: A randomised, double-blind, placebo-controlled trial, Lancet [P], vol 374, issue 9699, The Lancet Publishing Group, United Kingdom, pp. 1423-1431.
Schneider, H., Lam, L., Lokuge, A., Krum, H., Naughton, M.T., Smit, P.D.V., Bystrzycki, A., Eccleston, D., Federman, J., Flannery, G., Cameron, P., 2009, B-type natriuretic peptide testing, clinical outcomes, and health services use in emergency department patients With dyspnea a randomized trial, Annals Of Internal Medicine [P], vol 150, issue 6, American College of Physicians, United States, pp. 365-371.
Krum, H., Curtis, S.P., Kaur, A., Wang, H., Smugar, S.S., Weir, M.R., Laine, L., Brater, D.C., Cannon, C.P., 2009, Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: Multivariate analysis of the MEDAL program, European Journal of Heart Failure [P], vol 11, issue 6, Oxford University Press, United Kingdom, France, pp. 542-550.
Krum, H., Schlaich, M., Whitbourn, R., Sobotka, P., Sadowski, J., Bartus, K., Kapelak, B., Walton, A., Sievert, H., Thambar, S., Abraham, W., Esler, M.D., 2009, Catheter-based renal sympathetic denervation for resistant hypertension: A multicentre safety and proof-of-principle cohort study, Lancet [P], vol 373, issue 9671, The Lancet Publishing Group, United Kingdom, pp. 1275-1281.
Thom, O., Taylor, D.M., Wolfe, R., Cade, J.F., Paul, M.S., Krum, H., Wolfe, R.S.J., 2009, Comparison of a supra-sternal cardiac output monitor (USCOM) with the pulmonary artery catheter, British Journal Of Anaesthesia [P], vol 103, issue 6, Oxford University Press, United Kingdom, pp. 800-804.
Krum, H., 2009, Consider beta blockers for patients with heart failure, British Medical Journal [P], vol 338, issue b1728, BMJ Group, United Kingdom, pp. 1384-1385.
Chan, C.C., Reid, C.M., Aw, T., Liew, D., Haas, S.J., Krum, H., 2009, Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis, Journal of Hypertension [P], vol 27, Lippincott Williams & Wilkins, Ltd, United Kingdom, United States, pp. 2332-2341.
Zammit, S.C., Cox, A., Gow, R.M., Zhang, Y., Gilbert, R.E., Krum, H., Kelly, D.J., Williams, S.J., 2009, Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates, Bioorganic & Medicinal Chemistry Letters [P], vol 19, issue 24, Pergamon, United Kingdom, pp. 7003-7006.
Krum, H., Sanders, P., 2009, Expanding indications for pacing in chronic heart failure, Medical Journal Of Australia [P], vol 190, issue 9, Australasian Medical Publishing Company Pty. Ltd, Australia, pp. 470-471.
Krum, H., Swergold, G., Curtis, S.P., Kaur, A., Wang, H., Smugar, S.S., Weir, M.R., Laine, L., Brater, D.C., Cannon, C.P., 2009, Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study, Journal of Hypertension [P], vol 27, issue 4, Lippincott Williams & Wilkins, Ltd, UK, pp. 886-893.
Krum, H., Abraham, W., 2009, Heart failure, Lancet [P], vol 373, issue 9667, The Lancet Publishing Group, United Kingdom, pp. 941-955.
Connelly, K., Kelly, D.J., Zhang, Y., Prior, D.L., Advani, A., Cox, A., Thai, K., Krum, H., Gilbert, R.E., 2009, Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy, Circulation: Heart Failure [P], vol 2, issue 2, Lippincott Williams & Wilkins, USA, pp. 129-137.
Kemp, W.W., Colman, J., Thompson, K., Madan, A., Vincent, M., Chin-Dusting, J.P., Kompa, A.R., Krum, H., Roberts, S., 2009, Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial, Liver International [P], vol 29, issue 3, Wiley-Blackwell Munksgaard, Denmark, Germany, pp. 427-433.
Krum, H., 2009, Optimising management of chronic heart failure, Lancet [P], vol 374, issue 9704, The Lancet Publishing Group, United Kingdom, pp. 1808-1809.
Krum, H., Iyngkaran, P., Lekawanvijit, S., 2009, Pharmacologic management of the cardiorenal syndrome in heart failure, Current Heart Failure Reports [P], vol 6, issue 2, Current Medicine Group LLC, United States, pp. 105-111.
Becker, M.C., Wang, T.H., Wisniewski, L., Wolski, K., Libby, P., Luscher, T.F., Borer, J.S., Mascette, A.M., Husni, M.E., Solomon, D.H., Graham, D.Y., Yeomans, N.D., Krum, H., Ruschitzka, F., Lincoff, A.M., Nissen, S.E., 2009, Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis, American Heart Journal [P], vol 157, issue 4, Mosby, Inc., United States, pp. 606-612.
Schlaich, M., Sobotka, P., Krum, H., Whitbourn, R., Walton, A., Esler, M.D., 2009, Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept, Hypertension [P], vol 54, issue 6, Lippincott Williams & Wilkins, United States, pp. 1195-1201.
Schlaich, M., Sobotka, P., Krum, H., Lambert, E., Esler, M.D., 2009, Renal sympathetic-nerve ablation for uncontrolled hypertension, New England Journal Of Medicine [P], vol 361, issue 9, Massachusetts Medical Society, United States, pp. 932-934.
McGrady, M., Krum, H., 2009, Screening: The new frontier in heart failure management, Cardiovascular Therapeutics [P], vol E, Wiley-Blackwell Publishing Ltd, United Kingdom, pp. 1-3.
Ezekowitz, J.A., Hernandez, A.F., Starling, R.C., Yancy, C.W., Massie, B.M., Hill, J.A., Krum, H., Diaz, R., Ponikowski, P., Metra, M., Howlett, J.G., Gennevois, D., O'Connor, C.M., Califf, R.M., Fonarow, G.C., 2009, Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF), American Heart Journal [P], vol 157, issue 2, Mosby, Inc., USA, pp. 219-228.
Gheorghiade, M., Khan, S., Blair, J.E.A., Harinstein, M.E., Krum, H., Mukherjee, R., Pitt, B., 2009, The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction, American Heart Journal [P], vol 158, issue 3, Mosby, Inc., USA, pp. 437-443.
Rasmussen, H.H., Figtree, G.A., Krum, H., Bundgaard, H., 2009, The use of beta3-adrenergic receptor agonists in the treatment of heart failure, Current Opinion in Investigational Drugs [P], vol 10, issue 9, Current Drugs Ltd, United Kingdom, pp. 955-962.
Kemp, W.W., Kompa, A.R., Phrommintikul, A., Herath, C.B., Jia, Z., Angus, P.W., McLean, C., Roberts, S., Krum, H., 2009, Urotensin II modulates hepatic fibrosis and portal hemodynamic alterations in rats, American Journal Of Physiology-Gastrointestinal And..., vol 297, issue 4, American Physiological Society, United States, pp. 762-767.
Struthers, A., Krum, H., Williams, G.H., 2008, A comparison of the aldosterone-blocking agents eplerenone and spironolactone, Clinical Cardiology, vol 31, issue 4, John Wiley & Sons Inc, United States, pp. 153-158.
Flannery, G., Gehrig-Mills, R., Billah, B., Krum, H., 2008, Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers, American Journal of Cardiology, vol 101, issue 6, Excerpta Medica Inc, United States, pp. 865-869.
Myles, P.S., Smith, J.A., Knight, J., Cooper, D.J., Silbert, B., McNeil, J.J., Esmore, D.S., Buxton, B.F., Krum, H., Forbes, A.B., Tonkin, A.M., 2008, Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) Trial: Rationale and design, American Heart Journal, vol 155, issue 2, Mosby, Inc., United States, pp. 224-230.
Krum, H., 2008, Beta-blockers should remain as first-line therapy in the management of hypertension, International Journal of Clinical Practice, vol 62, issue 8, Wiley-Blackwell Publishing Ltd, United Kingdom, pp. 1137-1141.
Dobre, D., Van Veldhuisen, D.J., Goulder, M.A., Krum, H., Willenheimer, R., 2008, Clinical effects of initial 6 months monotherapy with bisoprolol versus enalapril in the treatment of patients with mild to moderate chronic heart failure. Data from the CIBIS III trial, Cardiovascular Drugs and Therapy, vol 22, issue 5, Springer, Netherlands, pp. 399-405.
Krum, H., 2008, Clinical investigations of statins in heart failure: Ventricular function and anti-remodeling, Heart Failure Clinics, vol 4, issue 2, WB Saunders Co, United States, pp. 177-186.
MacDonald, M.R., Petrie, M.C., Hawkins, N.M., Petrie, J.R., Fisher, M., McKelvie, R., Aguilar, D., Krum, H., McMurray, J.J., 2008, Diabetes, left ventricular systolic dysfunction, and chronic heart failure, European Heart Journal, vol 29, issue 10, Oxford University Press, United Kingdom, France, pp. 1224-1240.
Tobing, D., French, J., Varigos, J.D., Meehan, A.D., Billah, B., Krum, H., 2008, Do patients with heart failure appropriately undergo invasive procedures post-myocardial infarction? Results from a prospective multicentre study, Internal Medicine Journal, vol 38, issue 11, Wiley-Blackwell Publishing Asia, Australia, pp. 845-851.
Zomer, E., de Ridder, I., Kompa, A.R., Komesaroff, P.A., Gilbert, R.E., Krum, H., 2008, Effect of urotensin II on skin microvessel tone in diabetic patients without heart failure or essential hypertension, Clinical and Experimental Pharmacology and Physiology, vol 35, issue 10, Wiley-Blackwell Publishing Asia, Australia, pp. 1147-1150.
Phrommintikul, A., Tran, L., Kompa, A.R., Wang, B.H., Adrahtas, A., Cantwell, D., Kelly, D.J., Krum, H., 2008, Effects of a rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction, American Journal of Physiology: Heart and Circulatory Physiology, vol 294, issue 4, American Physiological Society, United States, pp. 1804-1814.
Nelson, M., Reid, C.M., Ames, D.A., Beilin, L.J., Donnan, G.A., Gibbs, P., Johnston, C.I., Krum, H., Storey, E., Tonkin, A.M., Wolfe, R.S.J., Woods, R.L., McNeil, J.J., 2008, Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: Results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study, Medical Journal of Australia, vol 189, issue 2, Australasian Medical Publishing Company Pty. Ltd., Australia, pp. 105-109.
Pitt, B., Ahmed, A., Love, T.E., Krum, H., Nicolau, J., Cardoso, J.S., Parkhomenko, A., Aschermann, M., Corbalan, R., Solomon, H., Shi, H., Zannad, F., 2008, History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure, Hypertension, vol 52, issue 2, Lippincott Williams & Wilkins, United States, pp. 271-278.
Krum, H., 2008, Hypertension fundamentals, Medical Journal of Australia, vol 188, issue 12, Australasian Medical Publishing Company Pty Ltd, Australia, p. 689.
Szollosi, I., Thompson, B.R., Krum, H., Kaye, D.M., Naughton, M.T., 2008, Impaired Pulmonary diffusing capacity and hypoxia in heart failure correlates with central sleep apnea severity, CHEST, vol 134, issue 1, American College of Chest Physicians, United States, pp. 67-72.
Kemp, W.W., Roberts, S., Krum, H., 2008, Increased circulating urotensin Ii in cirrhosis: Potential implications in liver disease, Peptides, vol 29, issue 5, Elsevier Inc., United States, pp. 868-872.
Brack, J., Sindone, A., Funston, R., Schneider, H., Skiba, M.A., Ueng, K., Krum, H., 2008, Is addition of angiotensin receptor blockade superior to increasing ACE inhibitor dose in patients with heart failure?, International Journal of Cardiology [P], vol 3.469, issue 3, Elsevier Ireland Ltd, Ireland, pp. 309-312.
Connelly, K., Gilbert, R.E., Krum, H., 2008, Letter by Connelly et al regarding article: Diastolic stiffness of the failing diabetic heart: Importance of fibrosis, advanced glycation end products, and myocyte resting tension, Circulation, vol 117, issue 23, Lippincott Williams & Wilkins, United States, p. 483.
Kompa, A.R., See, F., Lewis, D., Adrahtas, A., Cantwell, D., Wang, B.H., Krum, H., 2008, Long-term but not short-term p38 mitogen-activated protein kinase inhibition improves cardiac function and reduces cardiac remodeling post-myocardial infarction, Journal of Pharmacology and Experimental Therapeutics, vol 325, issue 3, American Society for Pharmacology and Experimental Therapeutics, United States, pp. 741-750.
Newton, P.J., Davidson, P., Macdonald, P.S., Ollerton, R., Krum, H., 2008, Nebulized furosemide for the management of dyspnea: Does the evidence support its use?, Journal of Pain and Symptom Management, vol 36, issue 4, Elsevier Inc, United States, pp. 424-441.
Fruhwald, F.M., Fahrleitner-Pammer, A., Obermayer-Pietsch, B., Goulder, M.A., Krum, H., Van Veldhuisen, D.J., Van de Ven, L., Verkenne, P., Pieske, B., Meyer, W., Willenheimer, R., 2008, Neurohormones as predictors of outcome in an elderly heart failure population naive of neurhormonal blockers: Results from the CIBIS III Neurohormonal Substudy, Open Heart Failure Journal, vol 1, issue 8, Bentham Open, Netherlands, pp. 9-16.
Cherry, C., Hoy, J.F., Altman, P., Rowe, J.S., Krum, H., Mills, J., Lewin, S.R., 2008, Phase 1 single dose studies to optimize the pharmacokinetics of DG17, a novel HIV-protease inhibitor pro-drug, using sodium bicarbonate and ritonavir, Current HIV Research [P], vol 6, issue 3, Bentham Science Publishers Ltd, The Netherlands, pp. 272-275.
Ghali, J., Anand, I.S., Abraham, W., Fonarow, G.C., Greenberg, B., Krum, H., Massie, B.M., Wasserman, S.M., Trotman, M., Sun, Y., Knusel, B., Armstrong, P., 2008, Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia, Circulation, vol 117, issue 4, Lippincott Williams & Wilkins, United States, pp. 526-535.
Krum, H., 2008, Spotlight on renin: Role of renin in heart failure and therapeutic potential of direct renin inhibition, Journal of the Renin-Angiotensin-Aldosterone-System, vol 9, Sage Science Press, United Kingdom, pp. 177-180.
Krum, H., Iyngkaran, P., 2008, The black dog and the weak heart: Comorbid depression in the patient with heart failure, Journal of Cardiac Failure, vol 14, issue 6, Churchill Livingstone, United States, Japan, pp. 465-466.
Kemp, W.W., Roberts, S., Komesaroff, P.A., Zomer, E., Krum, H., 2008, Urotensin II in chronic liver disease: In vivo effect on vascular tone, Scandinavian Journal of Gastroenterology, vol 43, issue 1, Informa Healthcare, UK, pp. 103-109.
Zimmet, H.S., Krum, H., 2008, Using Adult Stem Cells to Treat Heart Failure-Fact or Fiction?, Heart, Lung and Circulation, vol 17, issue S4, Elsevier Australia, Australia, pp. 48-54.
Clark, R., Yallop, J.J., Piterman, L., Croucher, J.L., Tonkin, A.M., Stewart, S., Krum, H., 2007, Adherence, adaptation and acceptance of elderly chronic heart failure patients to receiving healthcare via telephone-monitoring, The European Journal of Heart Failure, vol 9, issue 11, Elzevier Science BV, The Netherlands, pp. 1104-1111.
Krum, H., 2007, Challenges in trials evaluating statins in heart failure, Archives of Medical Science [P], vol 3, issue 4A, Termedia Wydawnictwo, Poland, pp. S142-S146.
Williams, A.D., Carey, M.F., Selig, S., Hayes, A., Krum, H., Patterson, J., Toia, D., Hare, D., 2007, Circuit Resistance Training in Chronic Heart Failure Improves Skeletal Muscle Mitochondrial ATP Production Rate-A Randomized Controlled Trial, Journal of Cardiac Failure, vol 13, issue 2, Churchill Livingstone, USA, pp. 79-85.
Haas, S.J., Hill, R., Krum, H., Liew, D.Y.H., Tonkin, A.M., Ioannides-Demos, L.L., Stephan, K.L., McNeil, J.J., 2007, Clozapine-associated myocarditis: A review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003, Drug Safety, vol 30, issue 1, Adis International Ltd, New Zealand, pp. 47-57.
Pepe, S., Marasco, S., Haas, S.J., Sheeran, F.L., Krum, H., Rosenfeldt, F.L., 2007, Coenzyme Q10 in cardiovascular disease, Mitochondrion, vol 7, Elsevier BV, The Netherlands & USA, pp. S154-S167.
Rosenfeldt, F.L., Haas, S.J., Krum, H., Hadj, A., Ng, K., Leong, J.Y., Watts, G.F., 2007, Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials, Journal of Human Hypertension, vol 21, issue 4, Nature Publishing Group, UK, pp. 297-306.
Ritzema-Carter, J., Melton, I.C., Richards, M., Crozier, I.G., Frampton, C., Doughty, R., Whiting, J.S., Kar, S., Eigler, N., Krum, H., Abraham, W., Troughton, R., 2007, Direct left atrial pressure monitoring in ambulatory heart failure patients: initial experience with a new permanent implantable device, Circulation, vol 116, issue 25, Lippincott Williams & Wilkins, USA, pp. 2952-2959.
Krum, H., Ashton, E.L., Reid, C.M., Kalff, V., Rogers, J., Amarena, J., Singh, B., Tonkin, A.M., 2007, Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure, Journal of Cardiac Failure, vol 13, issue 1, Churchill Livingstone, USA, pp. 1-7.
Kaye, D.M., Krum, H., 2007, Drug discovery for heart failure: a new era or the end of the pipeline?, Nature Reviews Drug Discovery, vol 6, issue 2, Nature Publishing Group, UK, pp. 127-139.
McMurray, J.J., Teerlink, J.R., Cotter, G., Bourge, R.C., Cleland, J.G., Jondeau, G., Krum, H., Metra, M., O'Connor, C.M., Parker, J.D., Torre-Amione, G., Van Veldhuisen, D.J., Lewsey, J., Frey, A., Rainisio, M., Kobrin, I., 2007, Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: The VERITAS randomized controlled trials, JAMA, vol 298, issue 17, American Medical Association, USA, pp. 2009-2019.
Connelly, K., Kelly, D.J., Zhang, Y., Prior, D.L., Martin, J., Cox, A., Thai, K., Feneley, M.P., Tsoporis, J., White, K.E., Krum, H., Gilbert, R.E., 2007, Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat, Cardiovascular Research, vol 76, issue 2, Oxford University Press, UK & France, pp. 280-291.
Krum, H., Bailey, M.J., Meyer, W., Verkenne, P., Dargie, H., Lechat, P., Anker, S.D., 2007, Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta-blocker use: Results of CIBIS II, Cardiology, vol 108, issue 1, Karger AG, Switzerland, pp. 28-34.
Kemp, W.W., Roberts, S., Krum, H., 2007, Increased circulating urotensin II in cirrhosis: Potential implications in liver disease, Peptides, vol E-Pub, Elsevier Inc, USA, pp. 1-5.
Phrommintikul, A., Haas, S.J., Elsik, M., Krum, H., 2007, Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis, Lancet, vol 369, issue 9559, The Lancet Publishing Group, UK, pp. 381-388.
Krum, H., Gilbert, R.E., 2007, Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders, Journal of Hypertension, vol 25, issue 1, Lippincott Williams & Wilkins Ltd, UK, pp. 25-35.
Wein, L., Wein, S., Haas, S.J., Shaw, J., Krum, H., 2007, Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: A meta-analysis of randomized controlled trials, Archives of Internal Medicine, vol 167, issue 14, American Medical Association, USA, pp. 1476-1486.
Clark, R.A., Eckert, K.A., Stewart, S., Phillips, S.M., Yallop, J.J., Tonkin, A.M., Krum, H., 2007, Rural and urban differentials in primary care management of chronic heart failure: new data from the CASE study, Medical Journal of Australia, vol 186, issue 9, Australasian Medical Publishing Company Pty Ltd, Australia, pp. 441-445.
Elsik, M., Krum, H., 2007, Should beta blockers remain first-line drugs for hypertension?, Australian Prescriber, vol 30, issue 1, National Prescribing Service Ltd, Australia, pp. 18-21.
Szollosi, I., Krum, H., Kaye, D., Naughton, M., 2007, Sleep Apnea in Heart Failure Increases Heart Rate Variability and Sympathetic Dominance, Sleep [P], vol 30, issue 11, Associated Professional Sleep Societies, Llc, US, pp. 1509-1514.
Martin, J., Krum, H., 2007, Statins and clinical outcomes in heart failure, Clinical Science, vol 113, issue 3, Portland Press Ltd, UK, pp. 119-127.
Krum, H., Latini, R., Maggioni, A.P., Anand, I., Masson, S., Carretta, E., Ingrilli, F., Pettinati, G., Glazer, R.D., Tognoni, G., Cohn, J.N., 2007, Statins and symptomatic chronic systolic heart failure: A post-hoc analysis of 5010 patients enrolled in Val-HeFT, International Journal of Cardiology, vol 119, issue 1, Elsevier Ireland Ltd, Ireland, pp. 48-53.
Phrommintikul, A., Haas, S.J., Krum, H., 2007, Target haemoglobin concentrations in chronic kidney disease - Authors' reply, The Lancet, vol 369, issue 9572, The Lancet Publishing Group, UK, pp. 1516-1517.
Szramka, M., Harriss, L.R., Ninnio, D., Windebank, E., Brack, J., Skiba, M.A., Krum, H., 2007, The effect of rapid lipid lowering with atorvastatin on autonomic parameters in patients with coronary artery disease, International Journal of Cardiology, vol 117, issue 2, Elsevier Ireland Ltd, Ireland, pp. 287-291.
Yancy, C.W., Krum, H., Massie, B.M., Silver, M.A., Warner Stevenson, L., Cheng, M., Kim, S., Evans, R., 2007, The second follow-up serial infusions of nesiritide (FUSION II) trial for advanced heart failure: Study rationale and design, American Heart Journal, vol 153, issue 4, Mosby Inc, USA, pp. 478-484.
Krum, H., Kemp, W.W., 2007, Therapeutic potential of blockade of the urotensin II system in systemic hypertension, Current Hypertension Reports, vol 9, issue 1, Current Science Inc, United States, pp. 53-58.
Kelly, D.J., Zhang, Y., Connelly, K., Cox, A., Martin, J., Krum, H., Gilbert, R.E., 2007, Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy, American Journal of Physiology: Heart and Circulatory Physiology, vol 293, issue 5, American Physiological Society, USA, pp. 2860-2869.
Kemp, W.W., Krum, H., Colman, J., Bailey, M.J., Yandle, T., Richards, M., Roberts, S., 2007, Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension, Liver International, vol 27, issue 9, Wiley-Blackwell Munksgaard, Denmark, pp. 1232-1239.
Ajani, A.E., Marwick, T.H., Krum, H., 2006, Aldosterone antagonists: a new treatment option for patients with post-myocardial infarction heart failure, Cardiovascular Revascularization Medicine, vol 7, issue 4, Elsevier Inc., USA, pp. 234-236.
Pitt, B., Ferrari, R., Gheorghiade, M., Van Veldhuisen, D.J., Krum, H., McMurray, J.J., Lopez-Sendon, J., 2006, Aldosterone blockade in post-acute myocardial infarction heart failure, Clinical Cardiology, vol 29, issue 10, John Wiley & Sons, Inc., USA, pp. 434-438.
Krum, H., Mohacsi, P., Katus, H.A., Tendera, M., Rouleau, J., Fowler, M.B., Coats, A.J.S., Roecker, E.B., Packer, M., 2006, Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study, American Heart Journal, vol 151, issue 1, Mosby Inc., USA, pp. 55-61.
Zimmet, H.S., Krum, H., 2006, Beta-blockers for treatment of heart failure in the elderly, Journal of Pharmacy Practice and Research, vol 36, issue 3, Society of Hospital Pharmacists of Australia, Australia, pp. 229-233.
Krum, H., Aw, T., Liew, D.Y.H., Haas, S.J., 2006, Blood pressure effects of COX-2 inhibitors, Journal of Cardiovascular Pharmacology, vol 47, issue Suppl 1, Lippincott Williams & Wilkins, USA, pp. S43-S48.
Yallop, J.J., Clark, R.A., Croucher, J.L., Wilson, A., Sellar, B.N., Piterman, L., Tonkin, A.M., Krum, H., 2006, CHAT - A study of a nurse-led system of care, Australian Nursing Journal, vol 14, issue 4, Australian Nursing Federation, Australia, p. 19.
Aw, T., Liew, D.Y.H., Tofler, G., Schneider, H.G., Morel-Kopp, M., Billah, B., Krum, H., 2006, Can the blood pressure effects of COX-2 selective inhibitors be explained by changes in plasma aldosterone levels?, Journal of Hypertension, vol 24, issue 10, Lippincott Williams & Wilkins, Ltd, UK, pp. 1979-1984.
Cannon, C., Curtis, S.P., FitzGerald, G.A., Krum, H., Kaur, A., Bolognese, J.A., Reicin, A.S., Bombardier, C., Weinblatt, M.E., van der Heijde, D., Erdmann, E., Laine, L., 2006, Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison, Lancet, vol 368, issue 18, The Lancet Publishing Group, UK, pp. 1771-1781.
Piterman, L., Zimmet, H.S., Krum, H., 2006, Chronic Heart Failure, Check, vol 410, RACGP, Australia, pp. 1-25.
Krum, H., Stewart, S., 2006, Chronic heart failure: time to recognise this major public health problem, Medical Journal of Australia, vol 184, issue 4, Australasian Medical Publishing Company Pty Ltd, Australia, pp. 147-148.
Krum, H., Ruschitzka, F., 2006, 'Class effect' amongst cardiac drugs: term of convenience or pharmacological reality?, International Journal of Clinical Practice, vol 60, issue 1, Blackwell Publishing Ltd, UK, pp. 2-5.
Willenheimer, R., Krum, H., Van Veldhuisen, D.J., Erdmann, E., 2006, Comment on "clinical trials update from the European Society of Cardiology meeting 2005: CIBIS-III, by JGF Cleland and others" [4], European Journal of Heart Failure, vol 8, issue 2, Elsevier BV, Netherlands, pp. 219-220.
Krum, H., Cameron, P.A., 2006, Diuretics in the Treatment of Heart Failure: Mainstay of Therapy or Potential Hazard?, Journal of Cardiac Failure, vol 12, issue 5, Churchill Livingstone, USA, pp. 333-335.
Krum, H., Meehan, A.D., Varigos, J.D., Loane, P.R., Billah, B., 2006, Does the presence of heart failure alter prescribing of drug therapy after myocardial infarction? A multicentre study, Medical Journal of Australia, vol 185, issue 4, Australasian Medical Publishing Company Pty Ltd, Australia, pp. 191-194.
Dulin, B.R., Krum, H., 2006, Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence, Current Opinion in Cardiology, vol 21, issue 4, Lippincott Williams & Wilkins, USA, pp. 393-399.
Ritzema-Carter, J.L.T., Smyth, D., Troughton, R.W., Crozier, I.G., Melton, I.C., Richards, A.M., Eigler, N., Whiting, J.S., Kar, S., Krum, H., Abraham, W.T., 2006, Dynamic myocardial ischemia caused by circumflex artery stenosis detected by a new implantable left atrial pressure monitoring device, Circulation, vol 113, issue 15, Lippincott Williams & Wilkins, USA, pp. e705-e706.
Phrommintikul, A., Cantwell, D., Kompa, A.R., Krum, H., 2006, Effects of specific rho kinase inhibition (GSK 576371) on collagen synthesis in isolated neonatal rat cardiac fibroblasts, European Heart Journal, vol 27, p. 786.
Krum, H., 2006, Eplerenone, Australian Prescriber, vol 29, issue 2, National Prescribing Service Ltd, Australia, pp. 32-33.
Krum, H., Jelinek, M.V., Stewart, S., Sindone, A., Atherton, J.J., Hawkes, A., 2006, Guidelines for the prevention, detection and management of people with chronic heart failure in Australia 2006, Medical Journal of Australia, vol 185, issue 10, Australasian Medical Publishing Company Pty Ltd, Australia, pp. 549-556.
Gilbert, R.E., Connelly, K., Kelly, D.J., Pollock, C.A., Krum, H., 2006, Heart failure and nephropathy: catastrophic and interrelated complications of diabetes., Clinical Journal of the American Society of Nephrology, vol 1, issue 2, American Society of Nephrology, USA, pp. 193-208.
Krum, H., Tavazzi, L., 2006, Heart rate variability in the LF band is closely related to BNP levels in heart failure. Data from the multicenter Valsartan Heart Failure Trial (Val-HeFT), European Heart Journal, vol 27, p. 15.
Ferro, A., Gilbert, R.E., Krum, H., 2006, Importance of renin in blood pressure regulation and therapeutic potential of renin inhibition, International Journal of Clinical Practice, vol 60, issue 5, Blackwell Publishing Ltd, UK, pp. 577-581.
Connelly, K., Kelly, D., Zhang, Y., Zhang, Y., Prior, D.L., Krum, H., Gilbert, R.E., 2006, Inhibition of PKC beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy, Circulation, vol 114, issue 18, p. 843.
Boyle, A.J., Whitbourn, R., Schlicht, S., Krum, H., Kocher, A., Nadurkar, H., Bergmann, S., Daniell, M., O'Day, J., Skerrett, D., Haylock, D., Gilbert, R.E., Itescu, S., 2006, Intra-coronary high-dose CD34+ stem cells in patients with chronic ischemic heart disease: a 12-month follow-up, International Journal of Cardiology, vol 109, issue 1, Elsevier Ireland Ltd, Ireland, pp. 21-27.
Connelly, K.A., Prior, D.L., Kelly, D.J., Feneley, M.P., Krum, H., Gilbert, R.E., 2006, Load-sensitive measures may overestimate global systolic function in the presence of left ventricular hypertrophy: A comparison with load-insensitive measures, American Journal of Physiology: Heart and Circulatory Physiology, vol 290, issue 4, American Physiological Society, USA, pp. H1699-H1705.
Zimmet, H.S., Haas, S.J., Itescu, S., Krum, H., 2006, Meta-analysis of randomized control trials using adult haemopoietic stem cells in the setting of acute myocardial infarction, European Heart Journal, vol 27, p. 278.
Krum, H., 2006, New pharmacological strategies for heart failure, Journal of Cardiac Failure, vol 12, issue 8, Churchill Livingstone, USA, p. 147.
McClean, D., Aragon, J., Jamali, A., Kar, S., Ritzema-Carter, J., Troughton, R., Krum, H., Doughty, R., Abraham, W., Whiting, J.S., Eigler, N., 2006, Noninvasive calibration of cardiac pressure transducers in patients with heart failure: an aid to implantable hemodynamic monitoring and therapeutic guidance, Journal of Cardiac Failure, vol 12, issue 7, Churchill Livingstone, USA, pp. 568-576.
Clark, R.A., Yallop, J.J., Wickett, D., Krum, H., Tonkin, A.M., Stewart, S., 2006, Nursing sans frontieres: A three year case study of multi-state registration of support nursing practice using information technology, Australian Journal of Advanced Nursing, vol 24, issue 1, Australian Nursing Federation, Australia, pp. 39-45.
Ghali, J., Anand, I., Abraham, W., Krum, H., Massie, B.M., Armstrong, P., 2006, Randomized, double-blind, placebo-controlled trial to assess the impact of darbepoetin alfa treatment on exercise tolerance in anemic patients with symptomatic heart failure: results from STAMINA-HeFT, European Heart Journal, vol 27, p. 166.
Krum, H., Tavazzi, L., Maggioni, A.P., 2006, Reduced spectral component of low frequency heart rate variability is an independent predictor of morbidity and mortality in heart failure. Data from Val-HeFT, Circulation, vol 114, issue 18, p. 418.
Yallop, J.J., Chan, B.G.Y., Piterman, L., Tonkin, A.M., Forbes, A.B., Davidson, P.M., Clark, R.A., Halcomb, E., Nangle, A., Stewart, S., Croucher, J.L., Krum, H., 2006, The chronic heart-failure assistance by telephone (CHAT) study: assessment of telephone support for vulnerable patients with chronic disease, Asia Pacific Family Medicine Online, vol 5, issue 2, Blackwell Publishing Asia, Australia, pp. 1-10.
Ajani, A.E., Szto, G., Duffy, S.J., Eccleston, D., Clark, D.J., Lefkovits, J., Chew, D.P., Warren, R., Black, A., New, G., Walton, A., Lew, R., Shaw, J., Horrigan, M., Sebastian, M., Yan, B.P., Brennan, A.L., Meehan, A.D., Reid, C.A., Krum, H., 2006, The foundation and launch of the Melbourne Interventional Goup: A collaborative interventional cardiology project, Heart Lung and Circulation, vol 15, issue 1, Blackwell Publishing Asia, Australia, pp. 44-47.
Macdonald, P.S., Hill, J., Krum, H., 2006, The impact of baseline HR and BP on the tolerability of carvedilol in the elderly: the COLA (Carvedilol Open Label Assessment) II Study, American Journal of Cardiovascular Drugs, vol 6, issue 6, Adis International Ltd, New Zealand, pp. 401-405.
Ponikowski, P., Van Veldhuisen, D.J., Willenheimer, R., Follath, F., Krum, H., Lechat, P., 2006, The interrelation between renal function and the efficacy of initial monotherapy with bisoprolol or enalapril followed by their combination in patients with heart failure - results of CIBIS-III, European Heart Journal, vol 27, pp. 341-342.
Krum, H., Tonkin, A.M., 2006, The rosuvastatin impact on ventricular remodeling cytokines and neurohormones (UNIVERSE) study, Journal of the American College of Cardiology, vol 47, issue 4, pp. 61-62.
Krum, H., Hill, J., Fruhwald, F., Sharpe, C., Abraham, G., Zhu, J., Poy, C., Kragten, J.A., 2006, Tolerability of beta-blockers in elderly patients with chronic heart failure: the COLA II study, The Eurpoean Journal of Heart Failure, vol 8, issue 3, Elsevier Science BV, Amderdam The Netherlands, pp. 302-307.
Zomer, E., Kompa, A.R., Komesaroff, P.A., Krum, H., 2006, Urotensin II is a vasoconstrictor in diabetic patients without heart failure or essential hypertension, European Heart Journal, vol 27, p. 532.
Xiang, G., Seki, T., Schuster, M.D., Witkowski, P., Boyle, A.J., See, F., Martens, T.P., Kocher, A., Sondermeijer, H.P., Krum, H., Itescu, S., 2005, Catalytic degradation of vitamin D up-regulated protein 1 mRNA enhances cardiomyocyte survival and prevents left ventricular remodeling after myocardial ischemia, The Journal of Biological Chemistry, vol 280, issue 47, The American Society for Biochemistry and Molecular Biology, Inc., USA, pp. 39394-39402.
Cameron, P.A., Krum, H., 2005, Chronic heart failure, Emergency Medicine Australasia (Print), vol 17, issue 2, Wiley-Blackwell Publishing Asia, Australia, pp. 99-101.
Piterman, L., Zimmet, H.S., Krum, H., Tonkin, A.M., Yallop, J.J., 2005, Chronic heart failure--optimising care in general practice., Australian Family Physician, vol 34, issue 7, Royal Australian College of General Practioners, Australia, pp. 547-553.
Packer, M., McMurray, J.J., Massie, B.M., Caspi, A., Charlon, V., Cohen-Solal, A., Kiowski, W., Kostuk, W., Krum, H., Levine, B., Rizzon, P., Soler, J., Swedberg, K., Anderson, S., Demets, D.L., 2005, Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study, Journal of Cardiac Failure, vol 11, issue 1, Churchill Livingstone, Philadelphia USA, pp. 12-20.
Krum, H., 2005, Could risk stratification aid the treatment of patients with acute decompensated heart failure?, Nature Clinical Practice Cardiovascular Medicine, vol 2, issue 7, Nature Publishing Group, UK, pp. 334-335.
Dulin, B., Haas, S.J., Abraham, W., Krum, H., 2005, Do elderly systolic heart failure patients benefit from beta blockers to the same extent as the non-elderly? meta-Analysis of >12,000 patients in large-Scale clinical trials, The American Journal of Cardiology, vol 95, Excerpta Medica, Inc., USA, pp. 896-898.
Sondermeijer, B., Kompa, A.R., Komesaroff, P.A., Krum, H., 2005, Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension, The American Journal of Hypertension, vol 18, issue 9, Elsevier Inc., USA, pp. 1195-1199.
Cantwell, D., Kompa, A.R., Krum, H., 2005, Effect of rho-kinase inhibition on collagen production in isolated cardiac fibroblasts, European Heart Journal, vol 26, p. 66.
Krum, H., Lambert, E., Windebank, E., Campbell, D.J., Esler, M., 2005, Effect on angiotensin II in receptor blockade in autonomic nervous system function in patients with essential hypertension, American Journal of Physiology: Heart and Circulatory Physiology, vol Epub, American Physiological Society, USA, pp. 1-31.
Willenheimer, R., Van Veldhuisen, D.J., Silke, B., Erdmann, E., Follath, F., Krum, H., Ponikowski, P., Skene, A., Van de Ven, L., Verkenne, P., Lechat, P., 2005, Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III, Circulation, vol 112, issue 16, Lippincott Williams & Wilkins, Philadelphia USA, pp. 2426-2435.
Pitt, B., White, H., Nicolau, J., Martinez, F., Gheorghiade, M., Aschermann, M., Van Veldhuisen, D.J., Zannad, F., Krum, H., Mukherjee, R., Vincent, J., 2005, Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure, Journal of the American College of Cardiology, vol 46, issue 3, Elsevier Inc., USA, pp. 425-431.
See, F., Kompa, A.R., Martin, J., Lewis, D.A., Krum, H., 2005, Fibrosis as a therapeutic target post-myocardial infarction, Current Pharmaceutical Design, vol 11, issue 4, Bentham Science Publishers Ltd, The Netherlands, pp. 477-487.
Macdonald, P., Hill, J.S., Krum, H., 2005, Impact of baseline heart rate and blood pressure on tolerability of carvedilol in elderly patients with chronic heart failure, European Heart Journal, vol 26, p. 76.
Martin, J., Denver, R.A., Bailey, M.J., Krum, H., 2005, In vitro inhibitory effects of Atorvastatin on cardiac fibroblasts: implications for ventricular remodelling, Clinical and Experimental Pharmacology and Physiology, vol 32, issue 9, Blackwell Publishing Asia, Australia, pp. 697-701.
Boyle, A.J., Kelly, D.J., Zhang, Y., Cox, A.J., Gow, R.M., Way, K., Itescu, S., Krum, H., Gilbert, R.E., 2005, Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction, Journal of Molecular and Cellular Cardiology, vol 39, issue 2, Academic Press, UK, pp. 213-221.
Campbell, D.J., Krum, H., Esler, M.D., 2005, Losartan increases bradykinin levels in hypertensive humans, Circulation, vol 111, issue 3, Lippincott Williams & Wilkins, USA, pp. 315-320.
Aw, T., Haas, S.J., Liew, D.Y.H., Krum, H., 2005, Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure, Archives of Internal Medicine, vol 165, issue 5, American Medical Assoication, USA, pp. 490-496.
McMurray, J.J., Cohen-Solal, A., Dietz, R., Eichhorn, E., Erhardt, L., Hobbs, F.D.R., Krum, H., Maggioni, A.P., McKelvie, R.S., Pina, I.L., Soler-Soler, J., Swedberg, K., 2005, Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice, The European Journal of Heart Failure, vol 7, issue 5, Elsevier BV, The Netherlands, pp. 710-721.
Krum, H., Haas, S.J., Eichhorn, E., Ghali, J., Gilbert, E., Lechat, P., Packer, M., Roecker, E.B., Verkenne, P., Wedel, H., Wikstrand, J., 2005, Prognostic benefit of beta-blockers in patients not receiving ACE-inhibitors, European Heart Journal, vol 26, issue 20, Oxford University Press, UK, pp. 2154-2158.
Teerlink, J.R., McMurray, J.J.V., Bourge, R.C., Cleland, J.G.F., Cotter, G., Jondeau, G., Krum, H., Metra, M., O'Connor, C.M., Parker, J.D., Torre-Amione, G., Van Veldhuisen, D.J., Frey, A., Rainisio, M., Kobrin, I., 2005, Tezosentan in patients with acute heart failure: Design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS), American Heart Journal, vol 150, Mosby, Inc., USA, pp. 46-53.
Krum, H., 2005, The Task Force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure, European Heart Journal, vol 26, Oxford University Press, UK, pp. 2472-2477.
Liew, D.Y.H., Krum, H., 2005, The cardiovascular safety of celecoxib, Future Cardiology, vol 1, issue 6, Future Medicine Ltd, UK, pp. 1-14.
Walton, A.S., Krum, H., 2005, The heartpod implantable heart failure therapy system, Heart, Lung and Circulation, vol 14, Blackwell Publishing Asia, Australia, pp. 31-33.
Hermann, M., Krum, H., Ruschitzka, F., 2005, To the heart of the matter: Coxibs, smoking and cardiovascular risk, Circulation, vol 112, issue 7, Lippincott, Williams and Wilkins, USA, pp. 941-945.
Martin, J., Kelly, D.J., Mifsud, S., Zhang, Y., Cox, A.J., See, F., Krum, H., Wilkinson-Berka, J.L., Gilbert, R.E., 2005, Tranilast attenuates cardiac matrix deposition in experimental diabetes: Role of transforming growth factor-beta, Cardiovascular Research, vol 65, Elsevier BV, The Netherlands, pp. 694-701.
Kemp, W.W., Roberts, S., Krum, H., 2005, Urotensin II: a vascular mediator in health and disease, Current Vascular Pharmacology, vol 3, issue 2, Bentham Science Publishers Ltd, The Netherlands, pp. 159-168.
Elkadi, S., Krum, H., Storey, E., 2005, Vistio-spatial and verbal memory impairments in congestive heart failure patients, Journal of The Neurological Sciences, vol 238, Elsevier Science BV, Amsterdam Netherlands, p. S507.
Krum, H., Liew, D.Y.H., 2004, A feeling in the waters: diagnosis of heart failure using urinary natriuretic peptides, Clinical Science, vol 106, issue 2, Portland Press Ltd, United Kingdom, pp. 111-112.
Krum, H., Tonkin, A.M., Piterman, L., 2004, Bush telegraph - improving outcomes for rural and remote patients with chronic heart failure, Australian Family Physician, vol 33, issue 1-2, Royal Australian College of General Practitioners, Australia, pp. 76-77.
Krum, H., Liew, D.Y.H., Aw, T., Haas, S.J., 2004, Cardiovascular effects of selective cyclooxygenase-2 inhibitors, Expert Review of Cardiovascular Therapy, vol 2, issue 2, Future Drugs Ltd, UK, pp. 265-270.
Kompa, A.R., Thomas, W.G., See, F., Tzanidis, A., Hannan, R.D., Krum, H., 2004, Cardiovascular role of urotensin II: effect of chronic infusion in the rat, Peptides, vol 25, issue 10, Elsevier Inc., United States, pp. 1783-1788.
Kompa, A.R., Thomas, W.G., See, F., Tzanidis, A., Hannan, R.D., Krum, H., 2004, Cardiovascular role of urotensin II: effect of chronic infusion in the rat, Peptides, vol 25, issue 10, Elsevier Science Inc, USA, pp. 1738-1788.
Krum, H., 2004, Commentary: Trial finds administering carvedilol in hospital improves treatment adherence for people with heart failure, Evidence-based Cardiovascular Medicine, vol 8, issue 4, Elsevier Ltd, United Kingdom, pp. 319-320.
Willenheimer, R., Erdmann, E., Follath, F., Krum, H., Ponikowski, P., Silke, B., Van Veldhuisen, D.J., Van de Ven, L., Verkenne, P., Lechat, P., 2004, Comparison of treatment initiation with bisoprolol vs enalapril in chronic heart failure patients: rationale and design of CIBIS-III, The European Journal of Heart Failure, vol 6, issue 4, Elsevier BV, Netherland, pp. 493-500.
Krum, H., Hare, D.L., 2004, Correspondence, European Heart Journal, vol 25, issue 3, Oxford University Press, United Kingdom, France, p. 277.
Lim, M., Honisett, S.Y., Sparkes, C.D., Komesaroff, P.A., Kompa, A.R., Krum, H., 2004, Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure, Circulation, vol 109, issue 10, Lippincott, Williams & Wilkins, USA, pp. 1212-1214.
Connelly, K., Kelly, D.J., Langham, R.G., Krum, H., Gilbert, R.E., 2004, Drug therapy for the cardiac complication of diabetes, Drug Discovery Today: Therapeutic Strategies, vol 1, issue 2, Elsevier Ltd, UK, pp. 195-200.
Krum, H., Carson, P., Farsang, C., Maggioni, A.P., Glazer, R.D., Aknay, N., Chiang, Y., Cohn, J.N., 2004, Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT, The European Journal of Heart Failure, vol 6, issue 7, Elsevier, Amsterdam Netherlands, pp. 937-945.
Krum, H., Liew, D.Y.H., 2004, Eplerenone in the treatment of chronic heart failure, Expert Review of Cardiovascular Therapy, vol 2, issue 3, Future Drugs Ltd, UK, pp. 315-320.
Peterson, G.M., Fitzmaurice, K.D., Nauton, M., Vial, J.H., Stewart, K., Krum, H., 2004, Impact of pharmacist-conducted home visits on the outcomes of lipid-lowering drug therapy, Journal of Clinical Pharmacy and Therapeutics, vol 29, issue 1, Blackwell Publishing Ltd, UK, pp. 23-30.
Rouleau, J., Roecker, E.B., Tendera, M., Mohacsi, P., Krum, H., Katus, H.A., Fowler, M.B., Coats, A.J., Castaigne, A., Scherhag, A., Holcslaw, T.L., Packer, M., 2004, Influence of pretreatment systolic blood presure on the effect of Carvedilol in patients with severe Chronic Heart Failure: The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study, Journal of the American College of Cardiology, vol 43, issue 8, Elsevier Inc., USA, pp. 1423-1429.
Selig, S.E., Carey, M.F., Menzies, D.G., Patterson, J., Geerling, R.H., Williams, A.D., Bamroongsuk, V., Toia, D., Krum, H., Hare, D.L., 2004, Moderate-intensity resistance exercise training in patients with chronic heart failure improves strength, endurance, heart rate variability, and forearm blood flow, Journal of Cardiac Failure, vol 10, issue 1, Churchill Livingstone, USA, pp. 21-30.
Baruch, L., Glazer, R.D., Aknay, N., Vanhaecke, J., Heywood, J.T., Anand, I., Krum, H., Hester, A., Cohn, J.N., 2004, Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT), American Heart Journal, vol 148, issue 6, Mosby, Inc., USA, pp. 951-957.
Hartmann, F., Packer, M., Coats, A.J., Fowler, M.B., Krum, H., 2004, NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy, The European Journal of Heart Failure, vol 6, issue 3, Elsevier, Ansterdam Netherland, pp. 343-350.
Hartmann, F., Packer, M., Coats, A.J., Fowler, M.B., Krum, H., Mohacsi, P., Rouleau, J., Tendera, M., Castaigne, A., Anker, S.D., Amman-Zalan, I., Hoersch, S., Katus, H.A., 2004, Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial, Circulation, vol 110, issue 13, Lippincott Williams & Wilkins, USA, pp. 1780-1786.
Williams, A.D., Selig, S.E., Hare, D.L., Hayes, A., Krum, H., Patterson, J., Geerling, R.H., Toia, D., Carey, M.F., 2004, Reduced exercise tolerance in CHF may be related to factors other than impaired skeletal muscle oxidative capacity, Journal of Cardiac Failure, vol 10, issue 2, Churchill Livingstone, USA, pp. 141-148.
Mann, D.L., McMurray, J.J., Packer, M., Swedberg, K., Borer, J.S., Colucci, W.S., Djian, J., Drexler, H., Feldman, A., Kober, L., Krum, H., Liu, P., Nieminen, M., Tavazzi, L., Van Veldhuisen, D.J., Waldenstrom, A., Warren, M., westheim, A., Zannad, F., Fleming, T., 2004, Targeted anticytokine therapy in patients with Chronic Heart Failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL), Circulation, vol 109, issue 13, Lippincott, Williams & Wilkins, USA, pp. 1594-1602.
Krum, H., 2004, Tolerability of Carvedilol in heart failure: clinical trials experience, The American Journal of Cardiology, vol 93, issue 9A, Excerpta Medica, Inc., USA, pp. 58B-63B.
Gilbert, R.E., Douglas, S.A., Krum, H., 2004, Urotensin-II as a novel therapeutic target in the clinical management of cardiorenal disease, Current Opinion in Investigational Drugs, vol 5, issue 3, Current Drugs Ltd, UK, pp. 276-282.
Liew, D.Y.H., Schneider, H., Shaw, J., Krum, H., 2004, Utility of B-type natriuretic peptide as a screen for left ventricular dysfunction in patients with diabetes, Diabetes Care, vol 27, issue 3, American Diabetes Association, United States, p. 848.
See, F., Kompa, A.R., Krum, H., 2004, p38 MAP kinase as a therapeutic target in cardiovascular disease, Drug Delivery Today: Therapeutic Strategies, vol 1, issue 2, Elsevier, UK, pp. 149-154.
See, F., Thomas, W., Way, K., Tzanidis, A., Kompa, A.R., Lewis, D., Itescu, S., Krum, H., 2004, p38 Mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat, Journal of the American College of Cardiology, vol 44, issue 8, Elsevier Inc., USA, pp. 1679-1689.
See, F., Thomas, W.G., Way, K., Tzanidis, A., Kompa, A.R., Lewis, D., Itescu, S., Krum, H., 2004, p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat, Journal of the American College of Cardiology, vol 44, issue 8, Elsevier Inc., United States, pp. 1679-1689.
Liew, D.Y.H., Krum, H., 2003, Aldosterone receptor antagonists for hypertension. What do they offer?, Drugs, vol 63, issue 19, Adis International Ltd, New Zealand, pp. 1963-1972.
Haas, S.J., Vos, T., Gilbert, R., Krum, H., 2003, Are -blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials, American Heart Journal, vol 146, issue 5, Mosby, Inc., America, pp. 848-853.
Krum, H., 2003, Beta-blockers in chronic heart failure: what have we learned? What do we still need to know?, Current Opinion in Pharmacology, vol 3, issue 2, Elsevier Science Ltd, Kidlington UK, pp. 168-174.
Prisant, L.M., Krum, H., Roniker, B., Krause, S., Fakouhi, K., 2003, Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy?, Journal of Clinical Pharmacology, vol 43, issue 11, Sage Science Press (US), United States, pp. 1203-1210.
Krum, H., 2003, Clinical decision making in managing the 'difficult' patient with chronic heart failure: who, when, how, where?, European Heart Journal, vol 5, issue Supplement I, Oxford University Press, United Kingdom, France, pp. 188-196.
Krum, H., Skiba, M.A., Gilbert, R.E., 2003, Comparative metabolic effects of hydrochlorothiazide and indapamide in hypertensive diabetic patients receiving ACE inhibitor therapy, Diabetic Medicine, vol 20, issue 9, Blackwell Publishing Ltd, UK, pp. 708-712.
Krum, H., Liew, D.Y., 2003, Current status of endothelin blockade for the treatment of cardiovascular and pulmonary vascular disease, Current Opinion in Investigational Drugs, vol 4, issue 3, Current Drugs, UK, pp. 298-302.
Martin, J., Krum, H., 2003, Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class: are they clinically relevant?, Drug Safety, vol 26, issue 1, Adis International Limited, New Zealand, pp. 13-21.
Krum, H., Gilbert, R.E., 2003, Demographics and concomitant disorders in heart failure, The Lancet, vol 362, issue 9378, The Lancet Publishing Group, UK, pp. 147-158.
Tzanidis, A., Hannan, R.D., Thomas, W.G., Onan, D., Autelitano, D.J., See, F., Kelly, D.J., Gilbert, R.E., Krum, H., 2003, Direct actions of urotensin II on the heart. Implications for cardiac fibrosis and hypertrophy, Circulation Research, vol 93, issue 3, Lippincott Williams & Wilkins, United States, pp. 246-253.
Tzanidis, A., Hannan, R.D., Thomas, W.G., Onan, D., Autelitano, D.J., See, F., Kelly, D.J., Gilbert, R.E., Krum, H., 2003, Direct actions of urotensin II on the heart. Implications for cardiac fibrosis and hypertrophy, Circulation Research, vol 93, issue 3, Lippincott Williams & Wilkins, Philadelphia USA, pp. 246-253.
Krum, H., Roecker, E.B., Mohacsi, P., Rouleau, J., Tendera, M., Coats, A.J.S., Katus, H.A., Fowler, M.B., Packer, M., 2003, Effects of initiating carvediol in patients with severe chronic heart failure: results from the COPERNICUS study, The Journal of the American Medical Association, vol 289, issue 6, American Medical Association, USA, pp. 712-718.
Krum, H., Kompa, A.R., Hannan, R.D., Thomas, W.G., 2003, Emerging role of the urotensin II system in cardiovascular disease, Heart Drug, vol 3, issue 3, S. Karger AG, Switzerland, pp. 153-158.
Liew, D.Y., Martin, J., Krum, H., 2003, Eplerenone Pharmacia, Current Opinion in Investigational Drugs, vol 4, issue 3, Current Drugs Ltd, UK, pp. 316-322.
Nelson, M.R., Reid, C.M., Krum, H., McNeil, J.J., 2003, Factors influencing family physician adherence to hypertension treatment guideline recommendations on the initiation of pharmacotherapy: questionnaire survey, American Journal of Cardiovascular Drugs, vol 3, issue 6, Adis International Ltd, New Zealand, pp. 437-441.
Krum, H., Liew, D.Y., 2003, New and emerging drug therapies for the management of acute heart failure, Internal Medicine Journal, vol 33, issue 11, Blackwell Publishing Asia, Australia, pp. 515-520.
Krum, H., Liew, D.Y., 2003, New developments in the pharmacological treatment of chronic heart failure, Expert Opinion on Investigational Drugs, vol 12, issue 5, Ashley Publications Ltd, UK, pp. 751-757.
Xiang, S., Denver, R.A., Bailey, M.J., Krum, H., 2003, Physiologic determinants of endothelin concentrations in human saliva, Clinical Chemistry, vol 49, issue 12, American Association for Clinical Chemistry, Washington USA, pp. 2012-2019.
Nelson, M.R., Reid, C.M., Beilin, L.J., Donnan, G.A., Johnston, C.I., Krum, H., Storey, E., Tonkin, A.M., McNeil, J.J., 2003, Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly, Drugs & Aging, vol 20, issue 12, Adis International Ltd, Auckland New Zealand, pp. 897-903.
Krum, H., Liew, D.Y., 2003, Recent advances in the management of chronic heart failure, Australian Family Physician, vol 32, issue 1/2, Royal Australian College of General Practitioners, Australia, pp. 39-43.
Nelson, M.R., Reid, C.M., Krum, H., Ryan, P., Wing, L.M.H., McNeil, J.J., 2003, Short-term predictors of maintenance of Normotension after withdrawal of antihypertensive drugs in the second Australian National Blood Pressure Study (ANBP2), American Journal of Hypertension, vol 16, issue 1, Elsevier Inc., America, pp. 39-45.
Ashton, E.L., Liew, D.Y.H., Krum, H., 2003, Should patients with chronic heart failure be treated with statins?, Heart Failure Monitor, vol 3, issue 3, Remedica Medical Education and Publishing, United Kingdom, pp. 82-86.
Rosenfeldt, F.L., Hilton, D.J., Pepe, S., Krum, H., 2003, Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure, BioFactors, vol 18, IOS Press, Netherlands, Australia, pp. 91-100.
Gilbert, R.E., Krum, H., Wilkinson-Berka, J.L., Kelly, D.J., 2003, The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations, Diabetic Medicine, vol 20, issue 8, Blackwell Publishing Ltd, UK, pp. 607-621.
Krum, H., 2003, Tolerability of beta-blockers in chronic heart failure: reassurance needed, reassurance provided, Italian Heart Journal, vol 4, issue 4, CEPI - AIM Group, Italy, pp. 225-227.
Krum, H., Gilbert, R., 2003, Urotensin II: A new player in vascular and mycardial disease?, Clinical Science, vol 104, issue 1, Portland Press Ltd, UK, pp. 65-67.
Krum, H., 2003, Using bisoprolol and carvedilol in chronic heart failure, Medicine Today, vol 4, issue 3, Medicine Today Pty Ltd, Australia, pp. 79-80.
Krum, H., Tonkin, A.M., 2003, Why do phase III trials of promising heart failure drugs often fail? The contribution of regression to the truth, Journal of Cardiac Failure, vol 9, issue 5, Churchill Livingstone Inc Medical Publishers, Philadelphia USA, pp. 364-367.
Sondermeijer, H.P., van Marle, A.G., Kamen, P.W., Krum, H., 2002, Acute Effects of Caffeine on Heart Rate Variability, American Journal of Cardiology, vol 90, issue 8, Elsevier, USA, pp. 906-907.
Berakis, A., Williams, T.J., Naughton, M.T., Martin, J., Muhlmann, M., Krum, H., 2002, Altered Sympathetic and Parasympathetic Activity in Lung Transplantation Patients in Rest and Following Autonomic Pertubation, Chest, vol 136, issue 10, American College of Chest Physicians, USA, pp. 1192-1199.
Packer, M., Califf, R.M., Konstam, M.A., Krum, H., McMurray, J.J., Rouleau, J., Swedberg, K., 2002, Comparison of Omapatrilat and Enalapril in Patients with Chronic Heart Failure, Circulation, vol 106, issue 2, Lippincott Williams and Wilkins, USA, pp. r21-r27.
Liew, D., Krum, H., 2002, Diastolic heart failure in the elderley, Medicine Today, vol 3, issue 11, Medicine Today Pty Ltd, Australia, pp. 44-50.
Packer, M., Fowler, M.B., Roecker, E.B., Coats, A.J., Katus, H.A., Krum, H., Mohacsi, P., Rouleau, J., Tendera, M., Staiger, C., Holcsaw, T.L., Amman-Zalan, I., DeMets, D.L., 2002, Effect of Carvedilol on the Morbidity of Patients with Severe Chronic Heart Failure, Circulation, vol 106, Lippincott, Williams and Wilkins, USA, pp. 2194-2199.
Martin, P.T., Ninio, D., Krum, H., 2002, Effect of Endothelin Blockade on Basal and Stimulated Forearm Blood Flow in Patients with Essential Hypertension, Hypertension, vol 39, issue 3, Lippincott Williams and Wilkins, USA, pp. 821-824.
Krum, H., Nolly, H., Workman, D., Weizhong, H., Roniker, B., Krause, S., Kaffa, F., 2002, Efficacy of Eplerenone Added to Renin-Angiotensin Blockade in Hypertensive Patients, Hypertension, vol 40, issue 2, Lippincott Williams and Wilkins, USA, pp. 117-123.
Krum, H., Rogers, S., 2002, Left ventricular hypertrophy in chronic renal failure patients, Nephrology, vol 7, Blackwell Publishing, Carlton Vic Australia, pp. s64-s66.
Nelson, M.R., Reid, C.M., Krum, H., Muir, T., Ryan, P., McNeil, J.J., 2002, Predictors of normotension on withdrawal of antihypertensive drugs in elderly patients: prospective study in second Australian national blood pressure study cohort, British Medical Journal, vol 325, issue 7368, BMJ Publishing Group, UK, pp. 815-817.
Selig, S.E., Carey, M.F., Menzies, D.G., Patterson, J., Geerling, R.H., Williams, A.D., Bamroongsuk, V., Toia, D., Krum, H., Hare, D.L., 2002, Reliability of Isokinetic Strength and Aerobic Power Testing for Patients with Chronic Heart Failure, Journal of Cadiopulmonary Rehabilitation, vol 22, issue 4, Lippincott, Williams and Wilkins, USA, pp. 282-289.
Martin, J., Krum, H., 2002, Role of valsartan and other angiotensin receptor blockers in cardiovascular disease, Pharmacological Research, vol 46, issue 3, Academic Press, UK, pp. 203-212.
Howes, L., Krum, H., 2002, Selective cyclo-oxygenase-2 inhibitors and myocardial infarction, Drug Safety, vol 25, issue 12, Adis International Ltd, New Zealand, pp. 829-835.
Krum, H., McMurray, J.J., 2002, Statins and Chronic Heart Failure: do we Need a Large-Scale Outcome Trial?, Journal of American College of Cardiology, vol 39, issue 10, Elsevier Science Inc, USA, pp. 1567-1573.
Liew, D.Y.H., Krum, H., 2002, The role of aldosterone receptor blockade in the management of cardiovascular disease, Current Opinion in Investigational Drugs, vol 3, issue 10, Current Drugs Ltd, UK, pp. 1468-1473.
Krum, H., 2002, Tumor Necrosis Factor-Blockade as a Therapeutic Strategy in Heart Failure (RENEWAL and ATTACH): Unsuccessful, To Be Specific, Journal of Cardiac Failure, vol 8, issue 6, Churchill, Livingstone, USA, pp. 365-368.
Nelson, M.R., Reid, C., Krum, H., McNeil, J.J., 2001, A systematic review of predictors of maintenance of normotension after withdrawal of antihypertensive drugs, American Journal of Hypertension, vol 14, Elsevier Science, USA, pp. 98-105.
Katz, S., Krum, H., 2001, Acetylocholine-mediated vasodilation in the forearm circulation of patients with heart-failure: indirect evidence for the role of endothelium-derived hyperpolarizing factor, The American Journal of Cardiology, vol 87, Excerpta Medica, USA, pp. 1089-1092.
Krum, H., Tonkin, A., Currie, R., Djundjek, R., Johnston, C.I., 2001, Chronic heart failure in Australian general practice. The Cardiac Awareness Survey and Evaluation (CASE) study, Medical Journal of Australia, vol 174, Australian Medical Association, Australia, pp. 439-444.
Tzanidis, A., Lim, S., Hannan, R.D., See, F., Ugoni, A.M., Krum, H., 2001, Combined angiotensin and endothelin receptor blockade attenuates adverse cardiac remodeling post-myocardial infarction in the rat: possible role of transforming growth factor b1, Journal of Molecular and Cellular Cardiology, vol 33, Academic Press Ltd, London England, pp. 969-981.
Pellizzer, A., Kamen, P.W., Esler, M.D., Lim, S.S., Krum, H., 2001, Comparative effects of mibefradil and nifedipine gastrointestinal transport system on autonomic function in patients with mild to moderate essential hypertension, Journal of Hypertension, vol 19, Lippincott Williams & Wilkins, United Kingdom USA, pp. 279-285.
Krum, H., Denver, R.A., Tzanidis, A., Martin, P.T., 2001, Diagnostic and therapeutic potential of the endothelin system in patients with chronic heart failure, Heart Failure Reviews, vol 6, Kluwer Academic Publishers, Netherland, pp. 341-352.
Krum, H., 2001, Differentiation in the angiotensin II receptor 1 blocker class on autonomic function, Current Hypertension Reports, vol 3, issue S1, Current Science Inc, USA, pp. S17-S23.
Packer, M., Coats, A.J., Fowler, M.B., Katus, H.A., Krum, H., Mohacsi, P., Rouleau, J., Tendera, M., Castaigne, A., Roecker, E.B., Schultz, M.K., DeMets, D.L., 2001, Effect of carvedilol on survival in severe chronic heart failure, The New England Journal of Medicine, vol 344, issue 22, Massachusetts Medical Society, USA, pp. 1651-1658.
Martin, J., Krum, H., 2001, Eplerenone, Current Opinion in Investigational Drugs, vol 2, issue 4, Current Drugs Ltd, UK, pp. 521-524.
Krum, H., Tonkin, A.M., Jelinek, M.V., Harris, M., McNeil, J.J., Hunt, D., Kaye, D., Burrell, L.M., Arnolda, L., Keogh, A., Bergin, P., Walsh, W., Sindone, A., Hare, D.L., Holst, D.P., O'Driscoll, G., Horowitz, J.D., Richardson, M., 2001, Guidelines for management of patients with chronic heart failure in Australia, Medical Journal of Australia, vol 174, Australasian Medical Publishing Company Pty Ltd, Australia, pp. 459-466.
Holst, D.P., Kaye, D., Richardson, M., Krum, H., Prior, D., Aggarwal, A., Wolfe, R.S.J., Bergin, P., 2001, Improved outcomes from a comprehensive management system for heart failure, European Journal of Heart Failure, vol 3, Elsevier BV, Netherlands France, pp. 619-625.
Liew, D.Y.H., Krum, H., 2001, Management of chronic heart failure in the elderly patient, Clinical Geriatrics, vol 9, issue 10, HMP Communications, LLC, USA, pp. 24-34.
Krum, H., Gilbert, R.E., 2001, Management of the heart failure patient with diabetes, Medicographia, vol 23, issue 2, Les Laboratoires Servier, France, pp. 129-134.
Krum, H., 2001, New and emerging pharmacological strategies in the management of chronic heart failure, Current Opinion in Pharmacology, vol 1, Elsevier Ltd, UK, pp. 126-133.
Nelson, M.R., McNeil, J.J., Peeters, A., Reid, C., Krum, H., 2001, PBS/RPBS cost implications of trends and guideline recommendations in the pharmacological management of hypertension in Australia, 1994-1998, Medical Journal of Australia, vol 174, Australian Medical Association, Australia, pp. 565-568.
Krum, H., Lim, S.S., 2001, Pharmacoeconomics of beta-blockers: effective and cost-effective therapy in chronic heart failure, European Journal of Heart Failure, vol 3, Elsevier BV, Netherlands France, pp. 399-402.
Killalea, S., Krum, H., 2001, Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease, American Journal of Cardiovascular Drugs, vol 1, issue 3, Adis International Limited, New Zealand, pp. 193-204.
Martin, J., Krum, H., 2001, The heart failure journal club: a review of publications on heart failure in American Heart Journal, European Journal of Heart Failure, vol 3, Elsevier BV, Netherlands France, pp. 125-137.
Krum, H., Ninio, D., Macdonald, P., 2000, Baseline predictors of tolerability to carvedilol in patients with chronic heart failure, Heart, vol 84, British Medical Journal Publishing Group, London UK, pp. 615-619.
Martin, P., Tzanidis, A., Stein-Oakley, A.N., Krum, H., 2000, Effect of a highly selective endothelin-converting enzyme inhibitor on cardiac remodeling in rats after myocardial infarction, Journal of Cadiovascular Pharmacology, vol 36 suppl 1, Lippincott Williams and Wilkins, Philadelphia USA, pp. S367-S370.
Whorlow, S.L., Krum, H., 2000, Meta-Analysis of Effect of Beta-Blocker Theraphy on Mortality in Patients With New York Heart Association Class IV Chronic Congestive Heart Failure, The American Journal of Cardiology, vol 86, Excerpta Medica Inc, New York NY USA, pp. 886-889.
Snell, G.I., Kotsimbos, T.C., Levvey, B., Skiba, M.A., Rutherford, D., Kong, D.C.M., Williams, T.J., Krum, H., 2000, Pharmacokinetic assessment of oral ganciclovir in lung transplant recipients with cystic fibrosis, Journal of Antimicrobial Chemotherapy, vol 45, British Society for Antimicrobial Chemotherapy, UK, pp. 511-516.
Denver, R., Tzanidis, A., Martin, P., Krum, H., 2000, Salivary endothelin concentrations in the assessment of chronic heat failure, The Lancet, vol 355, Lancet Ltd, London UK, pp. 468-469.
Krum, H., 1999, Beta-blockers in heart failure. The new wave of clinical trials, Drugs, vol 58 issue 2, ADIS International, Auckland New Zealand, pp. 203-210.
Rayner, C.R., Ioannides-Demos, L.L., Spicer, W.J., D'Agostino, J., Bailey, M., Krum, H., 1999, Effect of collection tube on measured gentamicin and vancomycin concentrations, American Journal of Health-System Pharmacy, vol 56 issue 14, American Society of Health-System Pharmacists, Bethesda USA, pp. 1457-1458.
Hare, D., Ryan, T.M., Selig, S.E., Pellizzer, A., Wrigley, T.V., Krum, H., 1999, Resistance exercise training increases muscle strength, endurance and blood flow in patients with chronic heart failure, American Journal of Cardiology, vol 83 issue 12, Excerpta Media Inc, New York NY USA, pp. 1674-1677.
Krum, H., Martin, P., 1999, Role of endothelin in hypertension and therapeutic potential of endothelin blockade, Current Opinion in Cardiovascular, Pulmonary and Renal Investigational Drugs, vol 1 issue 3, Pharmapress Ltd., London UK, pp. 316-329.
Krum, H., 1999, Sympathetic activation and the role of beta-blockers in chronic heart failure, Australian and New Zealand Journal of Medicine, vol 29, The Royal Australian College of Physicians, Sydney NSW Australia, pp. 418-427.
Krum, H., 1998, Chronic heart failure, Current Therapeutics, vol 39, issue 8, Adis International Pty Ltd, French Forest NSW, pp. 19-24.
Krum, H., Karrasch, J., Hanser, A., Hare, D., Howes, L., Jackson, B., Leslie, P., 1998, Effect of angiotensin-converting enzyme inhibitor dosing interval on functional parameters in patients with chronic heart failure, American Heart Journal, vol 135 no 2 part 1, Mosby, St Louis USA, pp. 237-241.
Krum, H., Cranswick, N.E., Pellizzer, A., 1998, Effect of endothelin-I on endothelium-derived vascular responsiveness in man, Clinical Science, vol 95, Portland Press Ltd, London UK, pp. 151-155.
Krum, H., Shusterman, N., McMahon, S., Sharpe, N., 1998, Efficacy and safety of carvedilol in patients with chronic heart failure receiving concomitant amiodarone therapy, Journal of Cardiac Failure, vol 4 no4, Churchill Livingstone, Philadelphia USA, pp. 281-288.
Krum, H., Pellizzer, A., 1998, New and emerging drug treatments for hypertension, Australian Family Physician, vol 27, issue 4, The Royal Aust. College of General Practitioners, Forest Lodge NSW, pp. 235-242.
Krum, H., Pillay, P., 1998, New drugs: old drugs: B-Adrenoceptor blocking agents, Medical Journal in Australia, vol 168, issue 5, Australian Medical Publishing Company Limited, North Sydney NSW Australia, pp. 232-235.
Krum, H., Viskoper, R.J., Lacourciere, Y., Budde, M., Charlton, V., 1998, The effect of an endothelin-receptor antagonist, Bosentan, on blood pressure in patients with essential hypertension, The New England Journal of Medicine, vol 338 no 12, Massachusetts Medical Society, Waltham USA, pp. 784-790.
Krum, H., 1997, B-adrenoceptor blockers in chronic failure - a review, British Journal Clinical Pharmacology, vol 44, Blackwell Science Ltd, Oxford UK, pp. 111-118.
Pellizer, A., Krum, H., 1997, Clinical utility of digoxin in elderly patients in sinus rhythm with chronic heart failure, The Australian Journal of Hospital Pharmacy, vol 27, The Society of Hospital Pharmacists of Australia, South Melbourne Vic Australia, pp. 406-409.
Krum, H., 1997, Cricial assessment of calcium antagonists, Australian Family Physician, vol 26, Royal Australian College of General Practitioners, South Melbourne Vic Australia, pp. 841-848.
Krum, H., 1997, New drugs, old drugs; Inhibitors of the renin-angiotensin system, The Medical Journal of Australia, vol 167, Australian Medical Association, Sydney NSW Australia, pp. 38-40.
Krum, H., 1997, Reducing the burden of chronic heart failure, The Medical Journal of Australia, vol 167, Australian Medical Association, Sydney NSW Australia, pp. 61-62.
Krum, H., 1997, Therapeutic role of Inotropes, Current Therapeutics, vol 38, Adis Press, Frenchs Forest Australia, pp. 73-80.
Conference Proceedings
Lam, L.L.Y., Schneider, H., Andrianopoulos, N., Krum, H., Abramson, M.J., Mueller, C., Cameron, P., 2009, The effects of BNP testing at ED for acute SOB patients on clinical outcomes (meta-analysis), Heart, Lung and Circulation, Elsevier Australia, Australia, p. S190.
Smit, D., Lokuge, A., Lam, L., Bystrzycki, A., Cameron, P., Eccleston, D., Federman, J., Krum, H., Naughton, M., Schneider, H., 2008, B-type natriuretic peptide testing in patients with shortness of breath in the emergency department: a preliminary analysis of the accuracy of heart failure diagnosis, Annals of Emergency Medicine, Mosby, Inc., United States, p. 481.
Elkadi, S., Storey, E., Krum, H., 2006, What specific domains of cognition are impaired in patients with chronic heart failure?, Journal of the American College of Cardiology (ACC 06 Abstracts), pp. 38-39.
Pellizzer, A., Kamen, P.W., Esler, M.D., Lim, S., Krum, H., 1999, Comparative effects of T- and L- type calcium channel blockage on autonomic function in patients with mild-moderate hypertension, High Blood Pressure Research Council Aust. Inc. 21st annual Scientific Meeting, Program and Abstracts, Melbourne, Vic, 9-11th Dec, 1999, High Blood Pressure Research Council Aust Inc., Melbourne Vic Australia, p. 101.
Tzanidis, A., Lim, S., Hannan, R.D., Krum, H., 1999, Does endothelin mediate cardiac fibrosis following myocardial infarction via activation of transforming growth factor beta 1?, Circulation, Atlanta, USA, 7-10th Nov, 1999, Lippincott, Williams and Wilkins, Baltimore USA, p. 1-55.
Branley, P., Shiel, L.M., McNeil, J.J., McGrath, B.P., Krum, H., 1999, Effect of chronic renal failure on vascular structure and function in man, High Blood Pressure Research Council Aust. Inc. 21st Annual Scientific Meeting, Program and Abstracts, Melbourne Vic, 9-11th Dec, 1999, High Blood Pressure Research Council Aust, Inc., Melbourne Vic Australia, p. 100.
Whorlow, S.L., Krum, H., 1999, Effect of co-enzyme Q10 on cardiac function in patients with chronic heart failure: a meta-analysis of placebo-controlled trials, Cardia Society of Aust and NZ, 47th Annual Scientific Meeting, Final Program and Abstracts, Wellington NZ, 7-11th Aug 1999, Cardiac Society of Aust and NZ, Southbank Vic Australia, p. 124.
Pellizzer, A., Lim, S., Kamen, P.W., Straznicky, N.E., Krum, H., 1999, Effect of dietary lipid modification on autonomic function in premenopausal women, Cardiac Society of Aust. and NZ, 47th Annual Scientific Meeting, Final program and Abstracts, Wellington NZ, 7-11th Aug 1999, Cardiac Society of Aust and NZ, Southbank Vic Australia, p. 108.
Tzanidis, A., Lim, S., Martin, P., Krum, H., 1999, Endothelin and angiotensin II receptor antagonist treatment reduces mononuclear cell infiltration and miofibroblast activation post-myocardial infarction, Cardiac Society of Aust. and NZ, 47th Annual Scientific Meeting, Fnal Program and Abstracts, Wellington NZ, 7-11th Aug 1999, Cardiac Society of Aust. and NZ, Southbank Vic Australia, p. 118.
Tzanidis, A., Hannan, R.D., Krum, H., 1999, Endothelin mediated collagen synthesis in cardiac fibroblasts is regulated by transforming growth factor beta-1, High Blood Pressure Research Council Aust. Inc. 21st Annual Scientific Meeting - Program and Abstracts, Melbourne, Vic, 9-11th Dec 1999, High Blood Pressure Research Council Aust. Inc, Melbourne Vic Australia, p. 22.
Martin, P., Tzanidis, A., Maguire, J., Stein-Oakley, A., Krum, H., 1999, Enzyme inhibitor on cardiac remodeling in rats following myocardial infarction, High Blood Pressure Research Council Australia Inc. 21st Annual Scientific Meeting Program and Abstracts, Melbourne, Vic, 9-11th Dec, 1999, High Blood Pressure Research Council Aust Inc, Melbourne Vic Australia, p. 69.
Krum, H., Charlon, V., Widdman, T., Packer, M., 1999, Long-term, open-label experience with an endothelin receptor antagonist, Bosentan, in patients with severe chronic heart failure, Circulation, Atlanta USA, 7-11th Nov, 1999, Lippincott, Williams and Wilkins, Baltimore USA, p. 1-646.
Krum, H., Whorlow, S.L., 1999, Meta-analysis of effect of beta-blocker therapy on mortality in NYHA Class IV CHF patients, Circulation, Atlanta USA, 7-10 Nov, 1999, Lippincott, Williams and Wilkins, Baltimore USA, p. 1-203.
Krum, H., Tonkin, A., Currie, R., Djundjek, R., Johnston, C.I., 1999, Pharmacological management of chronic heart failure (CHF) in Australian general practice: tthe cardiac awareness survey and evaluation (case) study, Cardiac Society of Australia and New Zealand 47th Annual Scientific Meeting - Final Program and Extracts, Wellington, NZ, 7-11th Aug, 1999, Cardiac Society of Australia and New Zealand, Southbank Vic Australia, p. 142.
Nelson, M., Krum, H., McNeil, J.J., Ryan, P.F., Wing, L.M., Reid, C.M., 1999, Predictors of the short-term maintenance of Normotension post withdrawal of antihypertensive drugs in ANBP2, 1999 Taipei WONCA Asia Pacific Regional Conference, Taipei, Taiwan, p. 33.
Denver, R., Tzanidis, A., Martin, P., Krum, H., 1999, Salivary endothelin levels in the diagnosis and assessment of severity of chronic heart failure, Cardiac Society of aust. and NZ, 47th Annual Scientific Meeting, Final Program and Abstracts, Wellington, NZ, 7-11th August 1999, Cardiac Society of Australia and NZ, Southbank Vic Australia, p. 109.
Stephenson, H., Chapman, C.B., Killalea, S., McNeil, J.J., Krum, H., Talman, P., 1999, The development of compterised clinical decision support for the management of hypertension, High blood Pressure Research Council Aust Inc. 21st Annual Scientific Meeting, Program and Abstracts, Melbourne, Vic, 9-11th Dec, 1999, High Blood Pressure Research Council aust Inc., Melbourne Vic Australia, p. 117.
Nelson, M., Krum, H., McNeil, J.J., Ryan, P.F., L, W.M., Christopher, R.M., 1998, Withdrawal of Antihypertensive Drugs in General Practice Rationale and Design, People and their family doctors - Partners in care, Dublin Ireland, 14-18 June 1998, Radcliffe Medical Press Ltd, Oxford UK, p. 202.
Nelson, M., McNeil, J.J., Krum, H., Christopher, R.M., 1998, Withdrawal of antihypertensive drugs in the second Australian national blood pressure study (WAD in ANBP2). Interim results, Building Best Practice, Melbourne VIC, 11-15 October 1998, Royal Australian College of General Practitioners, Melbourne Vic Australia.
Other
Gilbert, R.E., Krum, H., 2006, Blocking the renin-angiotensin-aldosterone system: The next generation of therapeutic intervention, Presentation in the Rounds of the Divisions of Endocrinology and Metabolism and Cardiology, St Michael's Hospital, Snell Medical Communication Inc, Canada.
Martin, P., Pellizzer, A., Krum, H., 1998, Recent developments in antihypertensive pharmacotherapy, Modern Medicine of Australia, vol 41, issue 12, Modern Medicine of Australia Pty Ltd, Neutral Bay NSW, pp. 12-23.
Pellizer, A., Kamen, P.W., Toben, A., Thompson, B., Pierce, R., Ng, S., Krum, H., 1997, Patients with obstructive sleep apnoea have impaired baroreflex sensitivity, Abstract.
Nelson, M., Krum, H., McNeil, J.J., Reid, C.M., 1997, Which factors predict successful maintenance of normotension on the withdrawal of antihypertensive medication? An evidence-based review of the literature, Abstract at a non International conference.
Nelson, M.R., Krum, H., McNeil, J.J., Reid, C.M., 1997, Withdrawal of antihypertensive drugs (WAD) in the second Australian National Blood Pressure study (ANBP2): A nested case control study conducted in general practice, Abstract at a non International conference.
Postgraduate Research Supervisions
Current Supervision
- Program of Study:
- (DOCTORATE BY RESEARCH).
- Thesis Title:
- Blood pressure treatment in the elderly and its relation to cardiovascular outcomes and cost-effectiveness.
- Supervisors:
- Reid, C (Main), Krum, H (Associate).
- Program of Study:
- (DOCTORATE BY RESEARCH).
- Thesis Title:
- Cardiorenal syndrome: pathophysiology and role of uremic toxins.
- Supervisors:
- Wang, B (Main), Kompa, A (Associate), Krum, H (Associate).
- Program of Study:
- (DOCTORATE BY RESEARCH).
- Thesis Title:
- Drug-eluting stent utilization and impact in contemporary Australian interventional cardiology practice: insight from the Melbourne Interventional Group Registry.
- Supervisors:
- Krum, H (Main).
- Program of Study:
- (DOCTORATE BY RESEARCH).
- Thesis Title:
- Polypharmacy in the heart failure patient: are all prescribed drug classes required?.
- Supervisors:
- Krum, H (Main), Tonkin, A (Associate).
Completed Supervision
- Student:
- Branley, P.
- Program of Study:
- MEASUREMENT, ASSOCIATIONS AND BURDEN TO THE AUSTRALIAN HEALTH CARE SYSTEM OF RAPIDLY PROGRESSIVE ATHEROMA USING CIGARETTE SMOKING AND CHRONIC RENAL FAILURE AS EXAMPLES. (PHD) 1999.
- Supervisors:
- Mcneil, J (Main), Krum, H (Associate).
- Student:
- Denver, R.
- Program of Study:
- Diagnostic and pathophysiological importance of endothelin and other cytokines in human heart failure. (PHD) 2005.
- Supervisors:
- Krum, H (Main), Tzanidis, A (Associate).
- Student:
- Elsik, M.
- Program of Study:
- Myocardial fibrosis and extracellular matrix remodelling in chronic heart failure - novel treatment and monitoring strategies. (PHD) 2010.
- Supervisors:
- Krum, H (Main), Kelly, D (Associate), Taylor, A (Associate).
- Student:
- Haas, S.
- Program of Study:
- Pharmacovigilance & pharmacotherapy: safety, efficacy and impact of therapy upon the outcomes of heart failure and related co-morbidities. (PHD) 2009.
- Supervisors:
- Krum, H (Joint-Co), Vos, E (Honor-In-A).
- Student:
- Kemp, W.
- Program of Study:
- Vascular mediators in portal hypertension: the role of urotensin II. (PHD) 2010.
- Supervisors:
- Krum, H (Joint-Co), Roberts, S (Joint).
- Student:
- Lekawanvijit, S.
- Program of Study:
- Cardiorenal syndrome: pathophysiology, role of protein-bound uraemic toxins. (PHD) 2011.
- Supervisors:
- Krum, H (Main).
- Student:
- Lim, S.
- Program of Study:
- PRIORITY SETTING FOR THE PRIMARY PREVENTION OF CORONARY HEART DESEASE AND STROKE IN AUSTRALIA. (PHD) 2005.
- Supervisors:
- Krum, H (Main), Vos, E (Joint).
- Student:
- Martin, J.
- Program of Study:
- The pathophysiology of heart failure in type 2 diabetes. (PHD) 2005.
- Supervisors:
- Krum, H (Main).
- Student:
- Martin, P.
- Program of Study:
- THE ROLE OF ENDOTHELIN IN HYPERTENSION AND CHRONIC HEART FAILURE. (PHD) 2001.
- Supervisors:
- Krum, H (Main), Stein-Oakley ((Double Id)), A (Associate).
- Student:
- Mcgrady, M.
- Program of Study:
- Epidemiology of ventricular dysfunction and heart failure in high risk populations. (PHD) 2012.
- Supervisors:
- Krum, H (Main), Wolfe, R (Associate), Reid, C (Associate).
- Student:
- Nelson, M.
- Program of Study:
- ASPECTS OF PHARMACOLOGICAL MANAGEMENT OF HYPERTENSION IN GENERAL PRACTICE. (PHD) 2002.
- Supervisors:
- Reid, C (Main), Krum, H (Joint), Mcneil, J (Associate).
- Student:
- Pellizzer, A.
- Program of Study:
- THE EFFECT OF PHARMACOLOGICAL AND NON-PHARMACOLOGICAL THERAPY ON AUTOMATIC FUNCTION IN PATIENTS WITH CARDIOVASCULAR DISEASE. (PHD) 2002.
- Supervisors:
- Krum, H (Main).
- Student:
- See, F.
- Program of Study:
- Transforming growth factor beta-1 mediated fibrosis as a therapeutic target following myocardial infarction. (PHD) 2008.
- Supervisors:
- Krum, H (Main), Tzanidis, A (Associate).
- Student:
- Tran, L.
- Program of Study:
- Urotensin II signalling pathway in cardiovascular disease. (PHD) 2011.
- Supervisors:
- Krum, H (Main), Kompa, A (Associate), Wang, B (Associate).
On our site
A member of
Authorised by: Director, Office of Marketing and Communications.
Maintained by: eSolutions ServiceDesk.
Last updated: 18 February 2013.
Copyright © 2013 Monash University. ABN 12 377 614 012 -
Accessibility -
Caution -
Privacy
CRICOS Provider Number: 00008C
We acknowledge and pay respects to the Elders and Traditional Owners of the land on which our six Australian campuses stand. Information for Indigenous Australians